<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2016-08-09T20:31:45Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley &amp; Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:mnkd="http://www.mannkindcorp.com/20160630" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="mnkd-20160630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE126000--1610-Q0008_STD_0_20150810_0_1328615x1373094" unitRef="pure" decimals="INF" id="id_8322447_067664B6-5B2F-42D9-8287-636AC6517DBD_2001_1">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE126000--1610-Q0008_STD_0_20150810_0_1328615x1373094" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8322447_AEF5D19D-7408-4ED3-9E1A-19360BDD6857_3001_2">6.80</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE126000--1610-Q0008_STD_0_20150810_0_1328615x1373094_1330806x1324556" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8322447_AEF5D19D-7408-4ED3-9E1A-19360BDD6857_4001_4">6.80</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:SharePrice contextRef="eol_PE126000--1610-Q0008_STD_0_20150810_0_1328615x1373094_1330806x1324556_1335482x1331874" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8322447_AEF5D19D-7408-4ED3-9E1A-19360BDD6857_5001_3">4.82</us-gaap:SharePrice>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="eol_PE126000--1610-Q0008_STD_0_20151130_0" unitRef="shares" decimals="0" id="id_8322447_B0C0D22F-480E-4A94-8AF3-89B8A2DAC181_1003_4">159304</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160512_0_1333769x1344495" unitRef="iso4217_USD" decimals="-6" id="id_8322447_5B554D8B-F74C-4303-BA0F-0B253C4313AB_2001_3">5000000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160512_0_1333769x1514964" unitRef="iso4217_USD" decimals="-5" id="id_8322447_5B554D8B-F74C-4303-BA0F-0B253C4313AB_3001_0">12800000</us-gaap:LiabilitiesFairValueDisclosure>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE126000--1610-Q0008_STD_0_20160801_0" unitRef="shares" decimals="INF" id="id_8322447_018F488E-3308-44E1-9111-8683B17B8567_2_500005">478048448</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:OtherLongTermDebtNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20130701_0_1324497x1494756_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_8322447_14717241-23CB-4828-ABD5-B310D90178F6_1002_1">13100000</us-gaap:OtherLongTermDebtNoncurrent>
  <us-gaap:OtherLongTermDebtCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20130701_0_1324497x1494756_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_8322447_14717241-23CB-4828-ABD5-B310D90178F6_1002_0">3200000</us-gaap:OtherLongTermDebtCurrent>
  <mnkd:ContingentLiability contextRef="eol_PE126000--1610-Q0008_STD_0_20130701_0_1324497x1494756_1328480x1426352_1335482x1328677" unitRef="iso4217_USD" decimals="INF" id="id_8322447_92EE771F-5032-4C78-85AB-E592AC06C213_4002_3">90000000</mnkd:ContingentLiability>
  <mnkd:AreaOfOfficeSpaceLeased contextRef="eol_PE126000--1610-Q0008_STD_0_20150531_0_1325994x1441734_1326002x1454078" unitRef="sqft" decimals="0" id="id_8322447_95291E5A-DAAB-421D-90CC-358FCB06C122_2001_0">12500</mnkd:AreaOfOfficeSpaceLeased>
  <us-gaap:DeferredFinanceCostsGross contextRef="eol_PE126000--1610-Q0008_STD_0_20150728_0_1328615x1373094" unitRef="iso4217_USD" decimals="-5" id="id_8322447_1F833340-A8F8-4BA7-A1AC-62861EC9E152_1001_0">800000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE126000--1610-Q0008_STD_0_20160531_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8322447_4BEA620A-A767-4AC8-9844-4A68E275984E_4001_4">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160531_0" unitRef="iso4217_USD" decimals="-5" id="id_8322447_4BEA620A-A767-4AC8-9844-4A68E275984E_4001_3">44700000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="eol_PE126000--1610-Q0008_STD_0_20160531_0_1333769x1344495" unitRef="shares" decimals="0" id="id_8322447_B0C0D22F-480E-4A94-8AF3-89B8A2DAC181_2001_1">12135921</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="eol_PE126000--1610-Q0008_STD_0_20160531_0_1333769x1344495_1335482x1328677" unitRef="shares" decimals="0" id="id_8322447_4BEA620A-A767-4AC8-9844-4A68E275984E_5001_2">12135921</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="eol_PE126000--1610-Q0008_STD_0_20160531_0_1333769x1514964" unitRef="shares" decimals="0" id="id_8322447_B0C0D22F-480E-4A94-8AF3-89B8A2DAC181_3001_0">36407765</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="eol_PE126000--1610-Q0008_STD_0_20160531_0_1333769x1514964_1335482x1328677" unitRef="shares" decimals="0" id="id_8322447_4BEA620A-A767-4AC8-9844-4A68E275984E_6001_1">36407765</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE126000--1610-Q0008_STD_0_20140923_0_1327036x1425803" unitRef="pure" decimals="INF" id="id_8322447_0F959FBF-8F32-421A-9783-170384498F8E_1001_0">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE126000--1610-Q0008_STD_0_20140923_0_1327036x1425803" unitRef="iso4217_USD" decimals="INF" id="id_8322447_C484292F-C790-4F1F-B682-2878DB17D559_1001_0">175000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE126000--1610-Q0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1002_42">107187000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <mnkd:CommonStockLoanedUnderShareLendingAgreementShares contextRef="eol_PE126000--1610-Q0008_STD_0_20150930_0" unitRef="shares" decimals="INF" id="id_8322447_9C3219CC-629C-4000-86CD-FC7A4352350F_1001_0">9000000</mnkd:CommonStockLoanedUnderShareLendingAgreementShares>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_33">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_36">700000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_38">477741850</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_35">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_37">477741850</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_32">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:OwnshareLendingArrangementSharesIssued contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8322447_65F1B81D-646D-4BCE-A117-77F55F3B46D7_1001_0">9000000</us-gaap:OwnshareLendingArrangementSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_31">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_30">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_41">-2918060000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PurchaseObligation contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_EUR" decimals="-5" id="id_8322447_53734037-3993-4303-B9C6-8664395CE91D_2_1">95100000</us-gaap:PurchaseObligation>
  <us-gaap:PreferredStockValue contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_29" />
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_25">16668000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherDeferredCreditsCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_16">17680000</us-gaap:OtherDeferredCreditsCurrent>
  <us-gaap:LossContingencyAccrualCarryingValueNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_22">69978000</us-gaap:LossContingencyAccrualCarryingValueNoncurrent>
  <us-gaap:Liabilities contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_26">506011000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_43">139434000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-5" id="id_8322447_66122023-861C-4913-B409-4E21E043B5A5_4_6">197400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_5709F00D-0914-4537-A7E3-A0E488F14735_1_0">6536000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_19">18056000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_17">144431000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_40">-21000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_13">2849000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_42">-366577000</us-gaap:StockholdersEquity>
  <us-gaap:PurchaseObligationDueInSecondYear contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_EUR" decimals="-5" id="id_8322447_53734037-3993-4303-B9C6-8664395CE91D_2_3">23300000</us-gaap:PurchaseObligationDueInSecondYear>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_21">49521000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_5709F00D-0914-4537-A7E3-A0E488F14735_1_1">602000</us-gaap:InterestPayableCurrent>
  <us-gaap:DebtInstrumentUnamortizedPremium contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E5A47F32-EB9C-4185-9B5F-702C5CA183CA_1_1">545000</us-gaap:DebtInstrumentUnamortizedPremium>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E5A47F32-EB9C-4185-9B5F-702C5CA183CA_1_0">27690000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E5A47F32-EB9C-4185-9B5F-702C5CA183CA_1_3">27623000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:CommonStockValue contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_34">4777000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_39">2546727000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_1001_8">120018000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:PurchaseObligationDueInThirdYear contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_EUR" decimals="-5" id="id_8322447_53734037-3993-4303-B9C6-8664395CE91D_2_4">23300000</us-gaap:PurchaseObligationDueInThirdYear>
  <us-gaap:OtherCommitment contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-5" id="id_8322447_53734037-3993-4303-B9C6-8664395CE91D_1003_7">1900000</us-gaap:OtherCommitment>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_27" />
  <us-gaap:PurchaseObligationDueInFourthYear contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_EUR" decimals="-5" id="id_8322447_53734037-3993-4303-B9C6-8664395CE91D_2_5">23300000</us-gaap:PurchaseObligationDueInFourthYear>
  <us-gaap:OtherLongTermDebtCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_15">75452000</us-gaap:OtherLongTermDebtCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_5709F00D-0914-4537-A7E3-A0E488F14735_1_3">3114000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-5" id="id_8322447_E65ECB54-F52B-4CBB-AC79-937EA7317211_1001_0">30100000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_20">289706000</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_23">27623000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_14">10252000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_7">90764000</us-gaap:AssetsCurrent>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_32654C5D-F311-4785-A0D7-6A4614FE6605_1_1">1155000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_8">47422000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:UnamortizedDebtIssuanceExpense contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E5A47F32-EB9C-4185-9B5F-702C5CA183CA_1_2">612000</us-gaap:UnamortizedDebtIssuanceExpense>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_2">63733000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="INF" id="id_8322447_4980ED30-6448-42A4-9957-986EEC09FD32_2_4">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:InventoryNet contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_4">2866000</us-gaap:InventoryNet>
  <us-gaap:DeferredCostsCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_5">22742000</us-gaap:DeferredCostsCurrent>
  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-5" id="id_8322447_00EACDAF-6F30-4A26-B20F-D77B738A6FE6_1_1">56800000</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_1001_7">167440000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:Assets contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_10">139434000</us-gaap:Assets>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_32654C5D-F311-4785-A0D7-6A4614FE6605_1_0">1491000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_32654C5D-F311-4785-A0D7-6A4614FE6605_1_2">220000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_9">1248000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_6">1423000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <mnkd:PurchaseObligationNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_24">52515000</mnkd:PurchaseObligationNoncurrent>
  <mnkd:PurchaseObligationCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_1_18">20986000</mnkd:PurchaseObligationCurrent>
  <mnkd:PurchaseObligationDueInRemainderOfFiscalYear contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_EUR" decimals="-5" id="id_8322447_53734037-3993-4303-B9C6-8664395CE91D_2_2">28800000</mnkd:PurchaseObligationDueInRemainderOfFiscalYear>
  <mnkd:AvailableBorrowingsUnderLoanAgreement contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0" unitRef="iso4217_USD" decimals="INF" id="id_8322447_C681745E-1DEA-4D44-BD75-C5BBD24FF3B3_1_0">0</mnkd:AvailableBorrowingsUnderLoanAgreement>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324199x1331109" unitRef="iso4217_USD" decimals="-5" id="id_8322447_C15BE42A-4D5A-4ADA-95D2-F53AB81A9025_1001_0">5600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324199x1335583" unitRef="iso4217_USD" decimals="-5" id="id_8322447_C15BE42A-4D5A-4ADA-95D2-F53AB81A9025_2001_1">7100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324497x1387193_1328480x1426352_1328615x1466792" unitRef="pure" decimals="INF" id="id_8322447_30015E80-FA89-4FE6-83E8-300598B5F3DF_1001_1">0.0875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324497x1387193_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_8322447_BD340945-D21E-4216-AB80-A6CC8E5E8033_2001_2">20000000</us-gaap:DebtInstrumentFaceAmount>
  <mnkd:LineOfCreditFacilityRestrictedBorrowingCapacity contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324497x1387193_1328480x1426352_1328615x1466792_1335482x1331874" unitRef="iso4217_USD" decimals="INF" id="id_8322447_3E32474D-943E-4A4A-AAE1-CEAA0696E715_1001_0">25000000</mnkd:LineOfCreditFacilityRestrictedBorrowingCapacity>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324497x1494756" unitRef="iso4217_USD" decimals="-5" id="id_8322447_66122023-861C-4913-B409-4E21E043B5A5_1004_3">15600000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324497x1494756_1324896x1324925" unitRef="iso4217_USD" decimals="-5" id="id_8322447_66122023-861C-4913-B409-4E21E043B5A5_1003_3">15600000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324497x1494756_1324896x1324925" unitRef="iso4217_USD" decimals="-5" id="id_8322447_92EE771F-5032-4C78-85AB-E592AC06C213_2001_1">15600000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:OtherLongTermDebtNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324497x1494756_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_8322447_92EE771F-5032-4C78-85AB-E592AC06C213_3001_2">8900000</us-gaap:OtherLongTermDebtNoncurrent>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324529x1510602_1325994x1469303" unitRef="iso4217_USD" decimals="-5" id="id_8322447_D6D9B6C4-976B-453D-BB1F-A6FD6D1FF547_1001_0">17600000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324896x1324925" unitRef="iso4217_USD" decimals="-5" id="id_8322447_66122023-861C-4913-B409-4E21E043B5A5_3_6">197400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324896x1324925_1325994x1359335" unitRef="iso4217_USD" decimals="-5" id="id_8322447_66122023-861C-4913-B409-4E21E043B5A5_2003_5">18100000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324896x1324925_1325994x1469303" unitRef="iso4217_USD" decimals="-5" id="id_8322447_66122023-861C-4913-B409-4E21E043B5A5_3003_4">62000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324896x1324925_1328615x1380739_1334317x1324465" unitRef="iso4217_USD" decimals="-5" id="id_8322447_66122023-861C-4913-B409-4E21E043B5A5_4003_1">21800000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324896x1324925_1328615x1483091" unitRef="iso4217_USD" decimals="-5" id="id_8322447_66122023-861C-4913-B409-4E21E043B5A5_5003_2">79900000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:DeferredRevenue contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325880x1332226_1325994x1469303_1327036x1425803" unitRef="iso4217_USD" decimals="-5" id="id_8322447_1E6AA981-3CAE-4325-ADCE-5220E7CF1B21_2001_2">17700000</us-gaap:DeferredRevenue>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1359335" unitRef="iso4217_USD" decimals="-5" id="id_8322447_66122023-861C-4913-B409-4E21E043B5A5_2004_5">18100000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1469303" unitRef="iso4217_USD" decimals="-5" id="id_8322447_66122023-861C-4913-B409-4E21E043B5A5_3004_4">62000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1469303_1327036x1425803" unitRef="iso4217_USD" decimals="INF" id="id_8322447_F82EF991-3FC1-4066-B71E-204DE9CC5CF7_2001_0">175000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:DeferredRevenue contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1469303_1327036x1425803" unitRef="iso4217_USD" decimals="-5" id="id_8322447_1E6AA981-3CAE-4325-ADCE-5220E7CF1B21_3001_0">150000000</us-gaap:DeferredRevenue>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1469303_1327036x1425803" unitRef="iso4217_USD" decimals="-5" id="id_8322447_F82EF991-3FC1-4066-B71E-204DE9CC5CF7_2001_2">62000000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1469303_1327036x1425803" unitRef="iso4217_USD" decimals="-5" id="id_8322447_F82EF991-3FC1-4066-B71E-204DE9CC5CF7_2001_1">70300000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:LongTermLoansPayable contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1469303_1327036x1425803" unitRef="iso4217_USD" decimals="-5" id="id_8322447_B29FCC3D-C2BC-4E5D-AFF2-9EF7C0655A75_3001_3">70000000</us-gaap:LongTermLoansPayable>
  <us-gaap:DeferredCosts contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1469303_1327036x1425803" unitRef="iso4217_USD" decimals="-5" id="id_8322447_1E6AA981-3CAE-4325-ADCE-5220E7CF1B21_3001_3">22700000</us-gaap:DeferredCosts>
  <mnkd:PotentialMilestonePaymentsToBeReceived contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1469303_1327036x1425803" unitRef="iso4217_USD" decimals="-5" id="id_8322447_1E6AA981-3CAE-4325-ADCE-5220E7CF1B21_3001_1">50000000</mnkd:PotentialMilestonePaymentsToBeReceived>
  <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1500563_1326002x1335383" unitRef="pure" decimals="INF" id="id_8322447_11F0D948-8392-4B5D-9B01-E333CD65232B_6001_2">0.0584</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1500563_1326002x1335383" unitRef="iso4217_USD" decimals="-5" id="id_8322447_11F0D948-8392-4B5D-9B01-E333CD65232B_6001_1">30100000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
  <us-gaap:LineOfCredit contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1500563_1326002x1335383" unitRef="iso4217_USD" decimals="-5" id="id_8322447_11F0D948-8392-4B5D-9B01-E333CD65232B_6001_0">49500000</us-gaap:LineOfCredit>
  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1500563_1326002x1335383" unitRef="iso4217_USD" decimals="-5" id="id_8322447_11F0D948-8392-4B5D-9B01-E333CD65232B_6001_3">7800000</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1328480x1426352_1328615x1466792" unitRef="pure" decimals="INF" id="id_8322447_30015E80-FA89-4FE6-83E8-300598B5F3DF_2001_0">0.0975</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1328480x1426352_1328615x1466792" unitRef="iso4217_USD" decimals="-5" id="id_8322447_BD340945-D21E-4216-AB80-A6CC8E5E8033_3001_0">60000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1328615x1380739_1334317x1324465" unitRef="iso4217_USD" decimals="-5" id="id_8322447_66122023-861C-4913-B409-4E21E043B5A5_4004_1">21800000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1328615x1483091" unitRef="iso4217_USD" decimals="-5" id="id_8322447_66122023-861C-4913-B409-4E21E043B5A5_5004_2">79900000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:PurchaseObligation contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1330148x1382533" unitRef="iso4217_USD" decimals="-6" id="id_8322447_C097A2EE-EF2D-421C-85F5-5CBA737DF179_2001_0">50000000</us-gaap:PurchaseObligation>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1333769x1344495" unitRef="shares" decimals="INF" id="id_8322447_B0C0D22F-480E-4A94-8AF3-89B8A2DAC181_2002_3">12135921</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1333769x1514964" unitRef="shares" decimals="INF" id="id_8322447_B0C0D22F-480E-4A94-8AF3-89B8A2DAC181_3002_2">36407765</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1333769x1514964" unitRef="iso4217_USD" decimals="-5" id="id_8322447_5B554D8B-F74C-4303-BA0F-0B253C4313AB_3003_0">18100000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1324247" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_2001_1">21590000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1324436" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_3001_6">437000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1325519" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_4001_3">67761000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1330541" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_5001_2">60584000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1334838" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_6001_0">3435000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1348884" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_7001_5">9519000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1349273" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_8001_4">4114000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE126000--1610-Q0008_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2001_41">120841000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_33">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_36">550000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_38">428670943</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_35">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_37">428670943</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_32">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_31">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_30">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_41">-2863229000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PreferredStockValue contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_29" />
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_25">15225000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherDeferredCreditsCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_16">17503000</us-gaap:OtherDeferredCreditsCurrent>
  <us-gaap:LossContingencyAccrualCarryingValueNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_22">62371000</us-gaap:LossContingencyAccrualCarryingValueNoncurrent>
  <us-gaap:Liabilities contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_26">476741000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_43">126412000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_8322447_FA1EAABD-62F0-448E-A596-468CA47ACEAA_4_5">150600000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_5709F00D-0914-4537-A7E3-A0E488F14735_2_0">5662000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_17">140231000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_40">-20000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_13">15599000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_42">-350329000</us-gaap:StockholdersEquity>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_21">49521000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_5709F00D-0914-4537-A7E3-A0E488F14735_2_1">615000</us-gaap:InterestPayableCurrent>
  <us-gaap:DebtInstrumentUnamortizedPremium contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E5A47F32-EB9C-4185-9B5F-702C5CA183CA_2_1">660000</us-gaap:DebtInstrumentUnamortizedPremium>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E5A47F32-EB9C-4185-9B5F-702C5CA183CA_2_0">27690000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E5A47F32-EB9C-4185-9B5F-702C5CA183CA_2_3">27613000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:CommonStockValue contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_34">4287000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_39">2508633000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_1002_8">119513000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:ConstructionPayableCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_5709F00D-0914-4537-A7E3-A0E488F14735_2_2">238000</us-gaap:ConstructionPayableCurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_27" />
  <us-gaap:OtherLongTermDebtCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_15">74582000</us-gaap:OtherLongTermDebtCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_5709F00D-0914-4537-A7E3-A0E488F14735_2_3">1414000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_20">268319000</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_23">27613000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_14">7929000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_7">76654000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_8">48749000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:UnamortizedDebtIssuanceExpense contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E5A47F32-EB9C-4185-9B5F-702C5CA183CA_2_2">737000</us-gaap:UnamortizedDebtIssuanceExpense>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_2">59074000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_3">23000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:DeferredCostsCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_5">13539000</us-gaap:DeferredCostsCurrent>
  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_8322447_00EACDAF-6F30-4A26-B20F-D77B738A6FE6_2_1">55800000</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_1002_7">168262000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:Assets contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_10">126412000</us-gaap:Assets>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_9">1009000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_6">4018000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <mnkd:PurchaseObligationNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_24">53692000</mnkd:PurchaseObligationNoncurrent>
  <mnkd:PurchaseObligationCurrent contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E8F423AD-5A40-43B7-A3EC-9C3C331A360A_2_18">12475000</mnkd:PurchaseObligationCurrent>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1324497x1494756" unitRef="iso4217_USD" decimals="-5" id="id_8322447_FA1EAABD-62F0-448E-A596-468CA47ACEAA_1004_3">14400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1324497x1494756_1324896x1324925" unitRef="iso4217_USD" decimals="-5" id="id_8322447_FA1EAABD-62F0-448E-A596-468CA47ACEAA_1003_3">14400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1324896x1324925" unitRef="iso4217_USD" decimals="-5" id="id_8322447_FA1EAABD-62F0-448E-A596-468CA47ACEAA_3_5">150600000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1324896x1324925_1325994x1469303" unitRef="iso4217_USD" decimals="-5" id="id_8322447_FA1EAABD-62F0-448E-A596-468CA47ACEAA_2003_4">36500000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1324896x1324925_1328615x1380739_1334317x1324465" unitRef="iso4217_USD" decimals="-5" id="id_8322447_FA1EAABD-62F0-448E-A596-468CA47ACEAA_3003_1">21300000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1324896x1324925_1328615x1483091" unitRef="iso4217_USD" decimals="-5" id="id_8322447_FA1EAABD-62F0-448E-A596-468CA47ACEAA_4003_2">78400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1325994x1469303" unitRef="iso4217_USD" decimals="-5" id="id_8322447_FA1EAABD-62F0-448E-A596-468CA47ACEAA_2004_4">36800000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1328615x1380739_1334317x1324465" unitRef="iso4217_USD" decimals="-5" id="id_8322447_FA1EAABD-62F0-448E-A596-468CA47ACEAA_3004_1">21300000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1328615x1483091" unitRef="iso4217_USD" decimals="-5" id="id_8322447_FA1EAABD-62F0-448E-A596-468CA47ACEAA_4004_2">78400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1324247" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_2002_1">21590000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1324436" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_3002_6">586000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1325519" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_4002_3">68434000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1330541" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_5002_2">60584000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1334838" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_6002_0">3435000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1348884" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_7002_5">9519000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1349273" unitRef="iso4217_USD" decimals="-3" id="id_8322447_864C20EA-6501-4617-ABA5-7BADE19E44E4_8002_4">4114000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE126000--1610-Q0008_STD_1_20140731_0" unitRef="iso4217_EUR" decimals="-5" id="id_8322447_53734037-3993-4303-B9C6-8664395CE91D_1_0">120100000</us-gaap:LongTermPurchaseCommitmentAmount>
  <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays contextRef="eol_PE126000--1610-Q0008_STD_1_20150810_0_1328615x1373094" id="id_8322447_265650AC-1449-4D68-A744-C731B72CCF1D_1001_3">P30D</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays>
  <us-gaap:DebtInstrumentRedemptionDescription contextRef="eol_PE126000--1610-Q0008_STD_1_20150810_0_1328615x1373094" id="id_8322447_265650AC-1449-4D68-A744-C731B72CCF1D_1001_0">On or after the date that is one year following the original issue date of the 2018 notes, the Company will have the right to redeem for cash all or part of the 2018 notes if the last reported sale price of its common stock exceeds 130% of the conversion price then in effect for 20 or more trading days during the 30 consecutive trading day period ending on the trading day immediately prior to the date of the redemption notice. The redemption price will equal the sum of 100% of the principal amount of the 2018 notes to be redeemed, plus accrued and unpaid interest.</us-gaap:DebtInstrumentRedemptionDescription>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE126000--1610-Q0008_STD_1_20150810_0_1328615x1373094" unitRef="pure" decimals="INF" id="id_8322447_5980239B-0EE5-4080-9E4D-5000B3D62C31_1001_0">1.00</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE126000--1610-Q0008_STD_1_20150810_0_1328615x1373094" unitRef="pure" decimals="4" id="id_8322447_AEF5D19D-7408-4ED3-9E1A-19360BDD6857_1001_0">147.0859</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="eol_PE126000--1610-Q0008_STD_1_20150810_0_1328615x1373094" unitRef="D" decimals="INF" id="id_8322447_265650AC-1449-4D68-A744-C731B72CCF1D_1001_2">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE126000--1610-Q0008_STD_1_20150810_0_1328615x1373094" id="id_8322447_067664B6-5B2F-42D9-8287-636AC6517DBD_1001_0">2018-08-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="eol_PE126000--1610-Q0008_STD_1_20150810_0_1328615x1373094" unitRef="pure" decimals="2" id="id_8322447_265650AC-1449-4D68-A744-C731B72CCF1D_1001_1">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
  <mnkd:PrincipalAmountPerShare contextRef="eol_PE126000--1610-Q0008_STD_1_20150810_0_1328615x1373094" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8322447_AEF5D19D-7408-4ED3-9E1A-19360BDD6857_1001_1">1000</mnkd:PrincipalAmountPerShare>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE126000--1610-Q0008_STD_1_20150810_0_1328615x1373094_1330806x1324556" unitRef="shares" decimals="-2" id="id_8322447_AEF5D19D-7408-4ED3-9E1A-19360BDD6857_2001_5">747100</us-gaap:ConversionOfStockSharesConverted1>
  <mnkd:ProfitLossSharingAgreementAllocationPercentage contextRef="eol_PE126000--1610-Q0008_STD_1_20160405_0_1325994x1469303_1327036x1425803" unitRef="pure" decimals="2" id="id_8322447_D730AED8-D930-4936-85B7-FF6C81132E54_1001_0">0.65</mnkd:ProfitLossSharingAgreementAllocationPercentage>
  <mnkd:ProfitLossSharingAgreementAllocationPercentage contextRef="eol_PE126000--1610-Q0008_STD_1_20160405_0_1327036x1425803" unitRef="pure" decimals="2" id="id_8322447_D730AED8-D930-4936-85B7-FF6C81132E54_2001_2">0.35</mnkd:ProfitLossSharingAgreementAllocationPercentage>
  <mnkd:ProceedsFromPutOptionsExercised contextRef="eol_PE126000--1610-Q0008_STD_1_20160414_0_1330148x1382533" unitRef="iso4217_USD" decimals="-5" id="id_8322447_C097A2EE-EF2D-421C-85F5-5CBA737DF179_1002_1">9200000</mnkd:ProceedsFromPutOptionsExercised>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="shares" decimals="0" id="id_8322447_1D988D42-E495-499A-9A8B-7224F9A5B992_2_4">40982544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_26">-14789000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="shares" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_13">399972000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_12">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:SalesRevenueNet contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_0">0</us-gaap:SalesRevenueNet>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_28">8737000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0DBC9591-D373-40CA-9E57-52462361A9EB_4_2">-6000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_14">-45688000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
  <us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_45">623000</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_6">-45790000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_11">-59569000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaidNet contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_44">6644000</us-gaap:InterestPaidNet>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_17">866000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_13">10146000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_16">10831000</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0DBC9591-D373-40CA-9E57-52462361A9EB_4_4">-59575000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_38">818000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_10">6000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_7">1403000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_11">6000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0DBC9591-D373-40CA-9E57-52462361A9EB_4_3">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_15">-6130000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_6">-12000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0D920E6C-6368-43EE-9362-B44DAB6E09F6_4_0">3778000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6341079E-0A0E-40E2-BC86-72199EC7DC79_4_0">5117000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_19">-7800000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_18">-2236000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_30">-8737000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_37">2050000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_8">1435000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_4">3778000</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_3">6359000</us-gaap:DepreciationAndAmortization>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_21">12968000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:PaidInKindInterest contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_5">265000</us-gaap:PaidInKindInterest>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_36">40000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_2">17115000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_3">21102000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_5">45790000</us-gaap:CostsAndExpenses>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_25">30000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_9">13753000</us-gaap:InterestExpenseDebt>
  <us-gaap:ManufacturingCosts contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_4_4">7573000</us-gaap:ManufacturingCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_39">9872000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_40">-13654000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_32">12820000</mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
  <mnkd:MilestonePayments contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_35">4220000</mnkd:MilestonePayments>
  <mnkd:InterestOnNotePayableToPrincipalStockholder contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_2_10">1435000</mnkd:InterestOnNotePayableToPrincipalStockholder>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0_1324529x1373094" unitRef="iso4217_USD" decimals="INF" id="id_8322447_E88BDEA2-16AC-439A-9986-152F9395BFAD_1004_0">0</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0_1325994x1441734_1326002x1454078" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E006D4E8-8B23-4465-A73B-3D7CDAF2205D_1004_0">65000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_8322447_1CA604D8-267A-4D12-BC8D-7F080DD021ED_1004_1">745000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_8322447_1CA604D8-267A-4D12-BC8D-7F080DD021ED_1004_0">17000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0_1333589x1324465" unitRef="shares" decimals="0" id="id_8322447_1D988D42-E495-499A-9A8B-7224F9A5B992_1002_3">14708590</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0_1333589x1331109" unitRef="shares" decimals="0" id="id_8322447_1D988D42-E495-499A-9A8B-7224F9A5B992_2002_0">19985768</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0_1333589x1332392" unitRef="shares" decimals="0" id="id_8322447_1D988D42-E495-499A-9A8B-7224F9A5B992_3002_1">2198173</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-Q0008_STD_181_20150630_0_1333589x1336129" unitRef="shares" decimals="0" id="id_8322447_1D988D42-E495-499A-9A8B-7224F9A5B992_4002_2">4090013</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_743ED1FB-D0C3-4CD2-BF7B-4D453D74A98D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;4. Accrued expenses and other current liabilities&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Accrued expenses and other current liabilities consist of the
 following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Salary and related expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,536&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,662&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Construction in progress&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,414&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued expenses and other current liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,252&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,929&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="shares" decimals="0" id="id_8322447_1D988D42-E495-499A-9A8B-7224F9A5B992_1_4">85549387</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_F4FEAE3A-C92D-4461-9C10-B67C6DFE3A2C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;7. Collaboration arrangement&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Sanofi License Agreement and Sanofi Supply Agreement&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As disclosed in Note 1 under Basis of Presentation, the Company
 entered into a license and collaboration agreement with Sanofi
 which was terminated effective April&amp;#xA0;4, 2016. On April&amp;#xA0;5,
 2016 the Company assumed responsibility for the worldwide
 development and commercialization of Afrezza from Sanofi. Under
 terms of the transition agreement, Sanofi continued to fulfill
 orders for Afrezza in the United States until the Company began
 distributing MannKind-branded product to major wholesalers during
 the week of July 25, 2016. As previously disclosed, worldwide
 profits and losses incurred by the Company and Sanofi that are
 specifically attributable or related to the development, regulatory
 filings, manufacturing, or commercialization of Afrezza, are shared
 65% by Sanofi and 35% by the Company until Sanofi ceases to
 distribute Afrezza.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company analyzed the agreements entered into with Sanofi to
 determine whether the consideration, or a portion thereof, could be
 recognized as revenue. Revenue is recognized when there is
 persuasive evidence that an arrangement exists, delivery has
 occurred or services have been rendered, the price is fixed or
 determinable and collection is reasonably assured. In addition,
 revenue arrangements with multiple elements are divided into
 separate units of accounting if certain criteria are met, including
 whether the delivered element has stand-alone value to the
 customer. When deliverables are separable, consideration received
 is allocated to the separate units of accounting based on the
 relative selling price of each deliverable and the appropriate
 revenue recognition principles are applied to each unit.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The assessment of multiple element arrangements requires judgment
 in order to determine the appropriate units of accounting and the
 points in time that, or periods over which, revenue should be
 recognized. Under the terms of the Sanofi License Agreement, Sanofi
 Supply Agreement and the Sanofi Loan Facility the Company
 determined that the arrangement contained significant deliverables
 including (i)&amp;#xA0;licenses to develop and commercialize Afrezza
 and to use the Company&amp;#x2019;s trademarks, (ii)&amp;#xA0;development
 activities, and (iii)&amp;#xA0;manufacture and supply services for
 Afrezza. Due to the proprietary nature of the manufacturing
 services being provided by the Company, the Company determined that
 all of the significant deliverables should be combined into a
 single unit of accounting. The Company believes that the
 manufacturing services are proprietary due to the fact that since
 the late 1990&amp;#x2019;s, the Company has developed proprietary
 knowledge and patented equipment and tools that are used in the
 manufacturing process of Afrezza. Due to the complexities of
 particle formulation and the specialized knowledge and equipment
 needed to handle the Afrezza powder, neither Sanofi nor any
 third-party contract manufacturing organization currently possesses
 the capability of manufacturing Afrezza.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In order for revenue to be recognized, the seller&amp;#x2019;s price to
 the buyer must be fixed and determinable. Given that as of
 June&amp;#xA0;30, 2016 the Company did not have the ability to estimate
 the amount of costs that would potentially be incurred under the
 profit and loss share provision related to the Sanofi License
 Agreement and the Sanofi Supply Agreement, the Company believes
 this requirement for revenue recognition has not been met. As such,
 the Company did not recognize any revenue pursuant to the Sanofi
 License Agreement or the Sanofi Supply Agreement for the three
 months ended June&amp;#xA0;30, 2016. The Company has recorded the
 $150.0 million up-front payment and $50.0&amp;#xA0;million from
 milestone payments as deferred payments from collaboration. In
 addition, as of June&amp;#xA0;30, 2016 the Company has recorded
 $17.7&amp;#xA0;million in Afrezza product shipments to Sanofi recorded
 as deferred sales from collaboration and recorded
 $22.7&amp;#xA0;million as deferred costs from collaboration. Deferred
 costs represent the costs directly related to the collaboration,
 not to exceed the amount of deferred sales, for which recognition
 of revenue has been deferred. During the quarter ended
 June&amp;#xA0;30, 2016, the Company&amp;#x2019;s portion of the profit
 sharing was $0.3 million, which resulted in the reclassification
 from current deferred payments from collaboration to Sanofi loan
 facility and profit/loss share obligation to reflect amounts owed
 to Sanofi.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Sanofi Loan Facility&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On September&amp;#xA0;23, 2014, the Company entered into the Sanofi
 Loan Facility, consisting of a senior secured revolving promissory
 note and a guaranty and security agreement (the &amp;#x201C;Security
 Agreement&amp;#x201D;) with an affiliate of Sanofi which provides the
 Company with a secured loan facility of up to $175.0 million to
 fund the Company&amp;#x2019;s share of net losses under the Sanofi
 License Agreement. In the event of certain future defaults under
 the Sanofi Loan facility agreement for which the Company is not
 able to obtain waivers, the lender under the Sanofi Loan Facility
 may accelerate all of the Company&amp;#x2019;s repayment obligations,
 and take control of the Company&amp;#x2019;s pledged assets, potentially
 requiring the Company to renegotiate the terms of its indebtedness
 on terms less favorable to the Company, or to immediately cease
 operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The obligations of the Company under the Sanofi Loan Facility are
 guaranteed by the Company&amp;#x2019;s wholly-owned subsidiary, MannKind
 LLC, and are secured by a first priority security interest in
 certain insulin inventory located in the United States and any
 contractual rights and obligations pursuant to which the Company
 purchases or has purchased such insulin, and a second priority
 security interest in the Company&amp;#x2019;s assets that secure the
 Company&amp;#x2019;s obligations under the Facility Agreement, as
 amended. In addition, the Company granted to Sanofi, as additional
 security for the obligations under the Sanofi Loan Facility, a
 first priority mortgage on the Company&amp;#x2019;s facility in
 Valencia, California, which has a carrying value of
 $17.6&amp;#xA0;million as of June&amp;#xA0;30, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Advances under the Sanofi Loan Facility bear interest at a rate of
 8.5%&amp;#xA0;per annum and are payable in-kind and compounded
 quarterly and added to the outstanding principal balance under the
 Sanofi Loan Facility. The Company is required to make mandatory
 prepayments on the outstanding loans under the Sanofi Loan Facility
 from its share of any profits (as defined in the Sanofi License
 Agreement) under the Sanofi License Agreement within 30 days of
 receipt of its share of any such profits. No advances may be made
 under the Sanofi Loan Agreement if Deerfield has commenced
 enforcement proceedings in connection with an event of default
 under the Facility Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The outstanding principal of all loans under the Sanofi Loan
 Facility, if not prepaid, will become due and payable on
 September&amp;#xA0;23, 2024 unless accelerated pursuant to the terms of
 the Sanofi Loan Facility. Additionally, if the Company sells its
 Valencia facility, the Company is required to prepay the loans
 under the Sanofi Loan Facility from the net cash proceeds of the
 sale within five business days of receipt. The maturity date of
 September&amp;#xA0;23, 2024 for repayment of the outstanding principal
 amount of the loans under the Sanofi Loan Facility is not affected
 by the termination of the Sanofi License Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company&amp;#x2019;s total cumulative portion of the loss sharing,
 including interest, was $70.0&amp;#xA0;million, of which $70.3 million
 was borrowed under the Sanofi Loan Facility as of June&amp;#xA0;30,
 2016. For the three months ended June&amp;#xA0;30, 2016, the
 Company&amp;#x2019;s portion of the profit sharing was $0.3&amp;#xA0;million
 under the Sanofi License Agreement, which is required to be applied
 as a prepayment against the balance owed under the Sanofi Loan
 Facility. The total amount owed to Sanofi is $70.0 million, which
 includes $4.3&amp;#xA0;million in paid-in-kind interest capitalized as
 principal.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Sanofi Loan Facility includes customary representations,
 warranties and covenants by the Company, including restrictions on
 its ability to incur additional indebtedness, grant certain liens
 and make certain changes to its organizational documents. Events of
 default under the Sanofi Loan Facility include: the Company&amp;#x2019;s
 failure to timely make payments due under the Sanofi Loan Facility;
 inaccuracies in the Company&amp;#x2019;s representations and warranties
 to the noteholder; the Company&amp;#x2019;s failure to comply with any
 of its covenants under any of the Sanofi Loan Facility or certain
 other related security agreements and documents entered into in
 connection with the Sanofi Loan Facility, subject to a cure period
 with respect to most covenants; the Company&amp;#x2019;s insolvency or
 the occurrence of certain bankruptcy-related events; and the
 failure of any material provision under any of the Sanofi Loan
 Facility or certain other related security agreements and documents
 entered into in connection with the Sanofi Loan Facility to remain
 in full force and effect. If one or more events of default occurs
 and is continuing, Sanofi may terminate its obligation to make
 advances under the Sanofi Loan Facility, and, if certain specified
 events of default (including the Company&amp;#x2019;s failure to timely
 make payments due under the Sanofi Loan Facility; the
 Company&amp;#x2019;s failure to comply with the negative covenants under
 the Sanofi Loan Facility limiting the Company&amp;#x2019;s ability to
 incur additional indebtedness or grant certain liens; the
 Company&amp;#x2019;s insolvency or the occurrence of certain
 bankruptcy-related events; or the failure of any material provision
 under any of the Sanofi Loan Facility or certain other related
 security agreements and documents entered into in connection with
 the Sanofi Loan Facility to remain in full force and effect) occur
 and are continuing, the noteholder may accelerate all of the
 Company&amp;#x2019;s repayment obligations under the Sanofi Loan
 Facility and otherwise exercise any of its remedies as a secured
 creditor. There can be no assurance that the noteholder would not
 choose to exercise these rights in the event such events were to
 occur.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_88011636-3726-43F3-9959-B6B4E57C7551_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;11. Commitments and contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Guarantees and Indemnifications
 &amp;#x2014;&lt;/i&gt;&lt;b&gt;&lt;i&gt;&amp;#xA0;&lt;/i&gt;&lt;/b&gt;In the ordinary course of its
 business, the Company makes certain indemnities, commitments and
 guarantees under which it may be required to make payments in
 relation to certain transactions. The Company, as permitted under
 Delaware law and in accordance with its Bylaws, indemnifies its
 officers and directors for certain events or occurrences, subject
 to certain limits, while the officer or director is or was serving
 at the Company&amp;#x2019;s request in such capacity. The term of the
 indemnification period is for the officer&amp;#x2019;s or
 director&amp;#x2019;s lifetime. The maximum amount of potential future
 indemnification is unlimited; however, the Company has a director
 and officer insurance policy that may enable it to recover a
 portion of any future amounts paid. The Company believes the fair
 value of these indemnification agreements is minimal. The Company
 has not recorded any liability for these indemnities in the
 accompanying condensed consolidated balance sheets. However, the
 Company accrues for losses for any known contingent liability,
 including those that may arise from indemnification provisions,
 when future payment is probable and the amount can be reasonably
 estimated. No such losses have been recorded to date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Litigation &amp;#x2014;&lt;/i&gt;&lt;b&gt;&lt;i&gt;&amp;#xA0;&lt;/i&gt;&lt;/b&gt;The Company is subject
 to legal proceedings and claims which arise in the ordinary course
 of its business. As of June&amp;#xA0;30, 2016, the Company believes
 that the final disposition of such matters will not have a material
 adverse effect on the financial position, results of operations or
 cash flows of the Company and no accrual has been recorded. The
 Company maintains liability insurance coverage to protect the
 Company&amp;#x2019;s assets from losses arising out of or involving
 activities associated with ongoing and normal business operations.
 The Company records a provision for a liability when it is both
 probable that a liability has been incurred and the amount of the
 loss can be reasonably estimated. The Company&amp;#x2019;s policy is to
 accrue for legal expenses in connection with legal proceedings and
 claims as they are incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Following the public announcement of Sanofi&amp;#x2019;s election to
 terminate the Sanofi License Agreement and the subsequent decline
 in the Company&amp;#x2019;s stock price, several complaints were filed
 in the U.S. District Court for the Central District of California
 (the &amp;#x201C;District Court&amp;#x201D;) against the Company and certain
 of its officers and directors on behalf of certain purchasers of
 its common stock. These complaints have now been consolidated into
 a single action. The amended complaint includes claims asserted
 under Sections 10(b) and 20(a) of the Exchange Act and has been
 pled as putative shareholder class actions. In general, the
 complaints allege that the Company and certain of its officers and
 directors violated federal securities laws by making materially
 false and misleading statements regarding the prospects for
 Afrezza, thereby artificially inflating the price of its common
 stock. The plaintiffs are seeking monetary damages and other
 relief. The Company will vigorously defend against the claims
 advanced.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Following the public announcement of Sanofi&amp;#x2019;s election to
 terminate the Sanofi License Agreement and the subsequent decline
 in the Company&amp;#x2019;s stock price, two motions were submitted to
 the district court at Tel Aviv (Economic Department) for the
 certification of a class action against the Company and certain of
 its officers and directors. In general, the complaints allege that
 the Company and certain of its officers and directors violated
 Israeli and U.S. securities laws by making materially false and
 misleading statements regarding the prospects for Afrezza, thereby
 artificially inflating the price of its common stock. The
 plaintiffs are seeking monetary damages. The Company will
 vigorously defend against the claims advanced.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Subsequent to the filing of the federal securities class action
 against the Company, a shareholder derivative complaint was filed
 in the Superior Court for the State of California, County of Los
 Angeles against certain of the Company&amp;#x2019;s directors and
 officers. The complaint alleges breaches of fiduciary duties by the
 defendants and other violations of law.&amp;#xA0;Among other
 allegations, the complaint alleges that the defendants caused the
 Company to make false and misleading statements or omissions of
 material fact regarding the Company&amp;#x2019;s business and the
 prospects for sales of Afrezza, thereby artificially inflating the
 price of the Company&amp;#x2019;s common stock. The plaintiff is seeking
 unspecified monetary damages and other relief, including reforms to
 the Company&amp;#x2019;s corporate governance and internal
 procedures.&amp;#xA0;The defendants will vigorously defend against the
 claims advanced.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Contingencies &amp;#x2014;&lt;/i&gt;&amp;#xA0;In connection with the
 Facility Agreement, on July&amp;#xA0;1, 2013 the Company also entered
 into a Milestone Rights Purchase Agreement (the &amp;#x201C;Milestone
 Agreement&amp;#x201D;) with Deerfield Private Design Fund and Horizon
 Sant&amp;#xE9; FLML S&amp;#xC1;RL (collectively, the &amp;#x201C;Milestone
 Purchasers&amp;#x201D;), pursuant to which the Company sold the
 Milestone Purchasers the Milestone Rights to receive payments up to
 $90.0 million upon the occurrence of specified strategic and sales
 milestones, including the first commercial sale of an Afrezza
 product in the United States and the achievement of specified net
 sales figures (see Note 13 &amp;#x2013; Facility Agreement).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Commitments &amp;#x2014;&lt;/i&gt;&amp;#xA0;On July&amp;#xA0;31, 2014, the
 Company entered into a supply agreement (the &amp;#x201C;Insulin Supply
 Agreement&amp;#x201D;) with Amphastar France Pharmaceuticals S.A.S., a
 French corporation (&amp;#x201C;Amphastar&amp;#x201D;), pursuant to which
 Amphastar manufactures for and supplies to the Company certain
 quantities of recombinant human insulin for use in Afrezza. Under
 the terms of the Insulin Supply Agreement, Amphastar is responsible
 for manufacturing the insulin in accordance with the
 Company&amp;#x2019;s specifications and agreed-upon quality standards.
 The Company has agreed to purchase annual minimum quantities of
 insulin through 2019 under the Insulin Supply Agreement of an
 aggregate total of approximately &amp;#x20AC;120.1&amp;#xA0;million, of
 which &amp;#x20AC;95.1&amp;#xA0;million is remaining at June&amp;#xA0;30, 2016.
 The annual minimum quantity for 2016 is &amp;#x20AC;28.8&amp;#xA0;million,
 of which &amp;#x20AC;3.4 has been purchased as of June 30, 2016, and the
 remaining annual minimum quantities will be
 &amp;#x20AC;23.3&amp;#xA0;million for the years ending December&amp;#xA0;31,
 2017 through 2019. The Company may request to purchase additional
 quantities of insulin over such annual minimum quantities and will
 incur a cancellation fee of approximately $5.2&amp;#xA0;million if not
 purchased (see Note 1&amp;#xA0;&amp;#x2014; Summary of Significant
 accounting policies). The company also has other firm commitments
 with other suppliers for an aggregate of $1.9 million. Based on the
 Company&amp;#x2019;s firm purchase commitments outstanding and lower of
 cost or market analysis, the Company has recorded a loss on
 purchase commitments amounting to $74,000 and $66,000 as of
 June&amp;#xA0;30, 2016 and December 31, 2015, respectively. These
 balances include losses in foreign currency at June&amp;#xA0;30, 2016,
 the Company recognized a loss on foreign currency translation of
 $2.0&amp;#xA0;million for the six months ended June 30, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Unless earlier terminated, the term of the Insulin Supply Agreement
 expires on December&amp;#xA0;31, 2019 and can be renewed for
 additional, successive two year terms upon 12 months&amp;#x2019; written
 notice given prior to the end of the initial term or any additional
 two year term. The Company and Amphastar each have normal and
 customary termination rights, including termination for material
 breach that is not cured within a specific time frame or in the
 event of liquidation, bankruptcy or insolvency of the other party.
 In addition, the Company may terminate the Insulin Supply Agreement
 upon two years&amp;#x2019; prior written notice to Amphastar without
 cause or upon 30 days&amp;#x2019; prior written notice to Amphastar if a
 controlling regulatory authority withdraws approval for Afrezza,
 provided, however, in the event of a termination pursuant to either
 of the latter two scenarios, the provisions of the Insulin Supply
 Agreement require the Company to pay the full amount of all unpaid
 purchase commitments due over the initial term within 60 calendar
 days of the effective date of such termination.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Under the terms of the Sanofi Supply Agreement, in the event that
 Sanofi terminates the Sanofi License Agreement for various reasons
 (including the reasons cited in its notice of termination to the
 Company), then upon written notice from the Company within
 30&amp;#xA0;days following the termination date, Sanofi is obligated to
 purchase up to $50&amp;#xA0;million of the Company&amp;#x2019;s insulin
 inventory as a percentage of each lot received or receivable by the
 Company (the &amp;#x201C;Insulin Put Option&amp;#x201D;). On April&amp;#xA0;14,
 2016, the Company provided Sanofi with written notice that it was
 exercising the Insulin Put Option. To date, $9.2&amp;#xA0;million was
 received for the sale of insulin inventory in connection with the
 Insulin Put Option, which was recorded as deferred payments from
 collaboration. As future insulin purchases are made under the
 purchase commitment and subject to the terms of the Insulin Put
 Option, additional amounts will be invoiced to Sanofi.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_BB6D3F6D-6108-4E83-8FFD-2BB434C0A098_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;9. Accounting for stock-based compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Total stock-based compensation expense recognized in the
 accompanying condensed consolidated statements of operations for
 the three and six months ended June&amp;#xA0;30, 2016 and 2015 was as
 follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,355&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,778&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 During the three months ended March&amp;#xA0;31, 2016, the Company
 issued stock awards to employees with a four-year vesting schedule.
 The grant date fair value of the 2,364,200 restricted stock units
 and 4,920,267 stock options issued was $2.2 million and $3.0
 million, respectively, with a grant date fair value per share of
 $0.92 and $0.61, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 During the three months ended June&amp;#xA0;30, 2016, the Company
 issued stock awards to employees with a four-year vesting schedule.
 The grant date fair value of the 1,088,050 restricted stock units
 and 1,140,200 stock options issued was $1.0 million and $0.7
 million respectively, with a grant date fair value per share of
 $0.91 and $0.62, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As of June&amp;#xA0;30, 2016, there was $5.6 million and $7.1 million
 of unrecognized compensation cost related to options and restricted
 stock units, respectively, which are expected to be recognized over
 the remaining weighted average vesting period of 3.0 years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 During the three months ended June 30, 2016, the Company granted
 certain executives stock options to purchase an aggregate of
 4,015,000 shares of common stock at a weighted average exercise
 price of $0.91 per share. These awards contain performance
 conditions based on achieving certain product sales targets. The
 grant date fair value of these awards is $3.0 million with a grant
 date fair value of $0.74 per share, as determined using a
 Black-Scholes option pricing model. As of June 30, 2016, no
 compensation cost has been recognized related to these awards as
 they are not considered probable of achievement within the next
 twelve months.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_7991201F-DF73-4876-9DEE-9BCF27629DC0_1_4">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_7991201F-DF73-4876-9DEE-9BCF27629DC0_1_3">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_7991201F-DF73-4876-9DEE-9BCF27629DC0_1_0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_018F488E-3308-44E1-9111-8683B17B8567_1_400002">0000899460</dei:EntityCentralIndexKey>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_6809EF5F-F980-4CCA-8886-12ECBF741A40_1_0">&lt;div&gt;&lt;strong&gt;&lt;em&gt;&lt;font size="2"&gt;Fair Value of Financial Instruments
 &amp;#x2014;&lt;/font&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#xA0;The
 carrying amounts reported in the accompanying financial statements
 for cash and cash equivalents, accounts payable and accrued
 liabilities approximate their fair value due to their relatively
 short maturities. The fair value of the cash equivalents, note
 payable&amp;#xA0;to related party, senior convertible notes, and the
 Facility Agreement are discussed in Note 8 &amp;#x2013; Fair Value of
 Financial Instruments.&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_BEA4EEC3-7E3C-4EE4-BBB7-744316D6DB7A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;2. Inventories&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Inventories consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Raw materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,491&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Work-in-process&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,155&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finished goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total Inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_26">-42267000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_2EBC6F27-963D-4A93-9DD6-F2A0D5DFBD2D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Potentially dilutive securities outstanding are summarized as
 follows (in shares):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of common stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,219,831&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,985,768&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vesting of restricted stock units&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,553,757&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,198,173&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,702,990&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,090,013&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion of senior convertible notes into common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,072,809&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,708,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85,549,387&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,982,544&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_CB248423-2A64-4A42-8DDD-0D8FFE1F4B01_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Senior convertible notes consist of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Senior Convertible notes&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Principal amount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unamortized premium&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;660&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unaccreted debt issuance costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net carrying amount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_97A04D55-3A19-4E94-B3E5-295392FE127F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following tables set forth the fair value of our financial
 instruments (in millions):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;June&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Financial liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Senior convertible notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Facility financing obligation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Milestone rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Sanofi Loan Facility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total financial liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;197.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;197.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Financial liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Senior convertible notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Facility financing obligation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Milestone rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Sanofi Loan Facility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total financial liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <dei:TradingSymbol contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_018F488E-3308-44E1-9111-8683B17B8567_1_400000">MNKD</dei:TradingSymbol>
  <dei:AmendmentFlag contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_7991201F-DF73-4876-9DEE-9BCF27629DC0_1_1">false</dei:AmendmentFlag>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_F23B1CF1-02F6-4463-AE11-7C98C5211FCC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;12. Income taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Management of the Company has evaluated the positive and negative
 evidence bearing upon the realizability of its deferred tax assets
 and concluded, in accordance with the applicable accounting
 standards, that net deferred tax assets should be fully
 reserved.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 ASC 740-10-25&amp;#xA0;Income Taxes Recognition&amp;#xA0;clarifies the
 accounting and disclosure for uncertainty in tax positions, as
 defined. This guidance seeks to reduce the diversity in practice
 associated with certain aspects of the recognition and measurement
 related to accounting for income taxes. The Company believes that
 its income tax filing positions and deductions will be sustained on
 audit and does not anticipate any adjustments that will result in a
 material change to its financial position. Therefore, no reserves
 for uncertain income tax positions have been recorded pursuant to
 this guidance. Tax years since 1993 remain subject to examination
 by the major tax jurisdictions in which the Company is subject to
 tax.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_8403522F-E803-4C04-9F8A-01273EA4F7C7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;1. Description of business and basis of presentation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The accompanying unaudited condensed consolidated financial
 statements of MannKind Corporation and its subsidiaries
 (&amp;#x201C;MannKind,&amp;#x201D; the &amp;#x201C;Company,&amp;#x201D;
 &amp;#x201C;we&amp;#x201D; or &amp;#x201C;us&amp;#x201D;), have been prepared in
 accordance with generally accepted accounting principles in the
 United States of America (&amp;#x201C;GAAP&amp;#x201D;) for interim financial
 information and with the instructions to Form 10-Q and Article 10
 of Regulation S-X of the Securities and Exchange Commission (the
 &amp;#x201C;SEC&amp;#x201D;). Accordingly, they do not include all of the
 information and footnotes required by GAAP for complete financial
 statements. The information included in this quarterly report on
 Form 10-Q should be read in conjunction with the audited
 consolidated financial statements and notes thereto included in the
 Company&amp;#x2019;s annual report on Form 10-K for the fiscal year
 ended December&amp;#xA0;31, 2015 filed with the SEC on March&amp;#xA0;15,
 2016 (the &amp;#x201C;Annual Report&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In the opinion of management, all adjustments, consisting only of
 normal, recurring adjustments, considered necessary for a fair
 presentation of the results of these interim periods have been
 included. The results of operations for the three and six months
 ended June&amp;#xA0;30, 2016 may not be indicative of the results that
 may be expected for the full year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the amounts reported in the financial statements and accompanying
 notes. Actual results could differ from those estimates or
 assumptions. The more significant estimates reflected in these
 accompanying financial statements involve assessing long-lived
 assets and deferred costs for impairment, accrued expenses,
 valuation of stock-based compensation and the determination of the
 provision for income taxes and corresponding deferred tax assets
 and liabilities and any valuation allowance recorded against net
 deferred tax assets. The estimation process often may yield a range
 of potentially reasonable estimates of the ultimate future outcomes
 and management must select an amount that falls within that range
 of reasonable estimates. This process may result in actual results
 differing materially from those estimated amounts used in the
 preparation of the financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Business &amp;#x2014;&lt;/i&gt;&lt;/b&gt;&amp;#xA0;MannKind is a
 biopharmaceutical company focused on the discovery, development and
 commercialization of therapeutic products for diseases such as
 diabetes. Our only approved product, Afrezza (insulin human)
 inhalation powder, is a rapid-acting inhaled insulin that was
 approved by the U.S. Food and Drug Administration (the
 &amp;#x201C;FDA&amp;#x201D;) on June&amp;#xA0;27, 2014 to improve glycemic
 control in adult patients with diabetes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&amp;#xA0;&lt;/i&gt;&lt;/b&gt;&amp;#x2014; The
 Company&amp;#x2019;s primary activities since incorporation have been
 establishing its facilities, recruiting personnel, conducting
 research and development, business development, business and
 financial planning, raising capital, and commercial manufacturing.
 In addition, the Company recently commenced commercial sales and
 marketing activities related to Afrezza. It is costly to develop
 and conduct clinical studies for therapeutic products, as well as
 to establish and maintain commercial sales and marketing
 capabilities. As of June&amp;#xA0;30, 2016, the Company had an
 accumulated deficit of $2.9 billion and has reported negative cash
 flow from operations since inception, other than for the nine
 months ended September&amp;#xA0;30, 2014, the year ended
 December&amp;#xA0;31, 2014, and for the three months ended
 March&amp;#xA0;31, 2015, as a result of receipt of the upfront payment
 and milestone payments from Sanofi-Aventis U.S. LLC
 (&amp;#x201C;Sanofi&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In May 2016, pursuant to a previously filed Form S-3 Registration
 Statement, which was declared effective by the SEC on
 April&amp;#xA0;27, 2016, the Company sold in an underwritten public
 offering 48,543,692 shares of its common stock, together with
 warrants to purchase up to 48,543,692 shares of the Company&amp;#x2019;s
 common stock. Net proceeds from this offering were approximately
 $47.4&amp;#xA0;million after deducting discounts and commissions to the
 underwriters and paying for offering expenses, excluding any future
 proceeds from the exercise of the warrants. (see Note 14 &amp;#x2014;
 Warrants).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 At June&amp;#xA0;30, 2016, the Company&amp;#x2019;s capital resources
 consisted of cash and cash equivalents of $63.7 million. The
 Company expects to continue to incur significant expenditures to
 support commercial manufacturing and sales and marketing of Afrezza
 and the development of other product candidates. The facility
 agreement (the &amp;#x201C;Facility Agreement&amp;#x201D;) with Deerfield
 Private Design Fund II, L.P. (&amp;#x201C;Deerfield Private Design
 Fund&amp;#x201D;) and Deerfield Private Design International II, L.P.
 (collectively, &amp;#x201C;Deerfield&amp;#x201D;) and the First Amendment to
 Facility Agreement and Registration Rights Agreement (the
 &amp;#x201C;First Amendment&amp;#x201D;) that resulted in additional sales of
 an additional tranche of notes (see Note
 13&amp;#xA0;&amp;#x2014;&amp;#xA0;Facility Agreement) requires the Company to
 maintain at least $25.0 million in cash and cash equivalents or
 available borrowings under the loan arrangement, dated as of
 October&amp;#xA0;2, 2007, between The Company and The Mann Group LLC
 (as amended, restated, or otherwise modified as of the date hereof,
 &amp;#x201C;The Mann Group Loan Arrangement&amp;#x201D;), as of the last day
 of each fiscal quarter. The Company will need to continue to incur
 expenses for the commercialization of Afrezza and will need to
 raise additional capital to finance such activities. The Company
 cannot be certain that it will be able to raise additional capital
 on favorable terms, or at all, which raises substantial doubt about
 the Company&amp;#x2019;s ability to continue as a going concern. The
 financial statements do not include any adjustments that might
 result from the outcome of this uncertainty.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On August&amp;#xA0;11, 2014, the Company executed a license and
 collaboration agreement (the &amp;#x201C;Sanofi License
 Agreement&amp;#x201D;) with Sanofi-Aventis Deutschland GmbH (which
 subsequently assigned its rights and obligations under the
 agreement to Sanofi), pursuant to which Sanofi was responsible for
 global commercial, regulatory and development activities for
 Afrezza. The Sanofi License Agreement became effective on
 September&amp;#xA0;23, 2014. The Company manufactured Afrezza at its
 manufacturing facility in Danbury, Connecticut to supply
 Sanofi&amp;#x2019;s demand for the product pursuant to a supply
 agreement dated August&amp;#xA0;11, 2014 (the &amp;#x201C;Sanofi Supply
 Agreement&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The Sanofi License Agreement and Sanofi Supply Agreement
 terminated, effective April 4, 2016, following which the Company
 assumed responsibility for the worldwide development and
 commercialization of Afrezza from Sanofi. Under the terms of the
 transition agreement, Sanofi continued to fulfill orders for
 Afrezza in the United States until the Company began distributing
 MannKind-branded product to major wholesalers during the week of
 July 25, 2016. The Company expects to commence recognition, likely
 within the third quarter of 2016, the deferred sales from
 collaboration, deferred costs from collaboration, and deferred
 payments from collaboration deferred as of June&amp;#xA0;30, 2016, as a
 result of the termination of the transition agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Under the Sanofi License Agreement, worldwide profits and losses,
 which are determined based on the difference between the net sales
 of Afrezza and the costs and expenses incurred by the Company and
 Sanofi that are specifically attributable or related to the
 development, regulatory filings, manufacturing, or
 commercialization of Afrezza, are shared 65% by Sanofi and 35% by
 the Company until Sanofi ceases to distribute Afrezza. As a result
 of this loss share provision, and because the Company does not
 currently have the ability to estimate the amount of costs that
 would potentially be incurred related to the Sanofi License
 Agreement, the amount of up-front cash payment or milestone
 payments that could be recognized as revenue is not fixed or
 determinable. In connection with the Sanofi License Agreement, an
 affiliate of Sanofi provided the Company with a secured loan
 facility (the &amp;#x201C;Sanofi Loan Facility&amp;#x201D;) of up to $175.0
 million to fund the Company&amp;#x2019;s share of net losses under the
 Sanofi License Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Additional funding sources that are, or in certain circumstances
 may be, available to the Company, include approximately $30.1
 million principal amount of available borrowings under The Mann
 Group Loan Arrangement. A portion of these available borrowings may
 be used to capitalize accrued interest into principal, upon mutual
 agreement of the parties, as it becomes due and payable under The
 Mann Group Loan Arrangement (see Note
 5&amp;#xA0;&amp;#x2014;&amp;#xA0;Related-party arrangements). The Company cannot
 provide assurances that its plans will not change or that changed
 circumstances will not result in the depletion of its capital
 resources more rapidly than it currently anticipates. The Company
 is seeking and will need to raise additional capital, whether
 through a sale of equity or debt securities, a strategic business
 collaboration with a pharmaceutical company, the establishment of
 other funding facilities, licensing arrangements, asset sales or
 other means, in order to continue the development and
 commercialization of Afrezza and other product candidates and to
 support its other ongoing activities. However, the Company cannot
 provide assurances that such additional capital will be available
 on acceptable terms or at all.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Certain prior year balances in the Statement of Cash Flows have
 been reclassified to conform to current year presentation.
 Specifically Interest incurred through borrowing under Sanofi Loan
 Facility and interest on note payable to principal stockholder have
 been reclassified from Accrued and other current liabilities and
 Other liabilities, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments
 &amp;#x2014;&lt;/i&gt;&lt;/b&gt;&amp;#xA0;The
 carrying amounts reported in the accompanying financial statements
 for cash and cash equivalents, accounts payable and accrued
 liabilities approximate their fair value due to their relatively
 short maturities. The fair value of the cash equivalents, note
 payable&amp;#xA0;to related party, senior convertible notes, and the
 Facility Agreement are discussed in Note 8 &amp;#x2013; Fair Value of
 Financial Instruments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Deferred costs from collaboration&lt;/i&gt;&lt;/b&gt;&amp;#xA0;&amp;#x2014; Deferred costs from
 collaboration represent the costs of product manufactured and sold
 to Sanofi, as well as certain direct costs associated with a firm
 purchase commitment entered into in connection with the
 collaboration with Sanofi. Such costs are deferred to the extent
 they are deemed recoverable through the recognition of future
 revenue associated with the collaboration and will be amortized as
 the associated revenue is recognized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Loss on purchase commitments&lt;/i&gt;&lt;/b&gt;&amp;#xA0;&lt;b&gt;&lt;i&gt;&amp;#x2014;&lt;/i&gt;&lt;/b&gt;&amp;#xA0;The
 Company assesses whether losses on long term purchase commitments
 should be accrued. Losses that are expected to arise from firm,
 non-cancellable, commitments for the future purchases of inventory
 items are recognized unless recoverable through firm sales
 contracts. When making the assessment, the Company considers
 whether it is able to renegotiate with its vendors and considering
 the Company&amp;#x2019;s lower of cost or market analysis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&amp;#xA0;&amp;#x2014; The Company accounts
 for its warrants as either equity or liabilities based upon the
 characteristics and provisions of each instrument and evaluation.
 Warrants classified as derivative liabilities are recorded on the
 Company&amp;#x2019;s balance sheet at their fair value on the date of
 issuance and are of sufficient authorized shares available to
 satisfy the obligations are revalued at each subsequent balance
 sheet date, with fair value changes recognized as increases or
 deductions to other income (expense) in the statement of
 operations. The Company estimates the fair value of its derivative
 liabilities using third party valuation analysis that utilizes
 option pricing models and assumptions that are based on the
 individual characteristics of the warrants or instruments on the
 valuation date, as well as assumptions expected volatility,
 expected life, yield, and risk-free interest rate. Warrants
 classified as equity are recorded within additional paid in capital
 at the issuance date and are not remeasured in subsequent periods,
 unless the underlying assumptions change to trigger liability
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Recently Issued Accounting Standards
 &amp;#x2014;&lt;/i&gt;&lt;/b&gt;&amp;#xA0;From time to time, new
 accounting pronouncements are issued by the Financial Accounting
 Standards Board (FASB) or other standard setting bodies that are
 adopted by the Company as of the specified effective date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In May 2014, the FASB issued ASU No. 2014-09 related to revenue
 recognition, which requires an entity to recognize the amount of
 revenue to which it expects to be entitled for the transfer of
 promised goods or services to customers. The standard requires a
 company to recognize revenue to depict the transfer of goods or
 services to customers in an amount that reflects the consideration
 it expects to be entitled to receive in exchange for those goods or
 services. In August 2015, the FASB issued ASU 2015-14, Revenue from
 Contracts with Customers (Topic 606): Deferral of the Effective
 Date, which delayed the effective date of the new standard from
 January&amp;#xA0;1, 2017 to January&amp;#xA0;1, 2018. The FASB also agreed
 to allow entities to choose to adopt the standard as of the
 original effective date. In March 2016, the FASB issued ASU
 No.&amp;#xA0;2016-08, Revenue from Contracts with Customers (Topic
 606): Principal versus Agent Considerations, which clarifies the
 implementation guidance on principal versus agent considerations.
 In April 2016, the FASB issued ASU No. 2016-10, Revenue from
 Contracts with Customers (Topic 606): Identifying Performance
 Obligations and Licensing, which clarifies certain aspects of
 identifying performance obligations and licensing implementation
 guidance.&amp;#xA0;In May 2016, the FASB issued ASU No. 2016-12,
 Revenue from Contracts with Customers (Topic 606): Narrow-Scope
 Improvements and Practical Expedients related to disclosures of
 remaining performance obligations, as well as other amendments to
 guidance on collectability, non-cash consideration and the
 presentation of sales and other similar taxes collected from
 customers.&amp;#xA0;The Company is assessing the potential impact of
 the new standards on its consolidated financial statements and has
 not yet selected a method of adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In August 2014, the FASB issued ASU No. 2014-15, which provides
 guidance on determining when and how reporting entities must
 disclose going-concern uncertainties in their financial statements.
 The new standard requires management to perform interim and annual
 assessments of an entity&amp;#x2019;s ability to continue as a going
 concern within one year of the date of issuance of the
 entity&amp;#x2019;s financial statements (or within one year after the
 date on which the financial statements are available to be issued,
 when applicable). Further, an entity must provide certain
 disclosures if there is &amp;#x201C;substantial doubt about the
 entity&amp;#x2019;s ability to continue as a going concern.&amp;#x201D; The
 ASU is effective for annual periods ending after December&amp;#xA0;15,
 2016, and interim periods thereafter; early adoption is permitted.
 The Company is evaluating the impact the adoption of ASU No.
 2014-15 will have on its consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic
 330): Simplifying the Measurement of Inventory. Topic 330,
 Inventory, currently requires an entity to measure inventory at the
 lower of cost or market. Market could be replacement cost, net
 realizable value, or net realizable value less an approximately
 normal profit margin. The amendments do not apply to inventory that
 is measured using last-in, first-out (LIFO) or the retail inventory
 method. The amendments apply to all other inventory, which includes
 inventory that is measured using first-in, first-out (FIFO) or
 average cost. The amendments are effective for fiscal years
 beginning after December&amp;#xA0;15, 2016, including interim periods
 within those fiscal years. The amendments should be applied
 prospectively with earlier application permitted as of the
 beginning of an interim or annual reporting period. The Company is
 evaluating the impact the adoption of ASU No. 2015-11 will have on
 its consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In January 2016, the FASB issued ASU No. 2016-01, Financial
 Instruments &amp;#x2014; Overall (Subtopic 825-10): Recognition and
 Measurement of Financial Assets and Financial Liabilities. The
 update is intended to improve the recognition and measurement of
 financial instruments. The ASU affects public and private
 companies, not-for-profit organizations, and employee benefit plans
 that hold financial assets or owe financial liabilities. The
 standard is effective for fiscal years beginning after
 December&amp;#xA0;15, 2017, including interim periods within those
 fiscal years. The Company is evaluating the impact the adoption of
 ASU No. 2016-01 will have on its consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In February 2016, the FASB issued ASU No.&amp;#xA0;2016-02, Leases
 (Topic 842). The new standard requires that all lessees recognize
 the assets and liabilities that arise from leases on the balance
 sheet and disclose qualitative and quantitative information about
 its leasing arrangements. The new standard will be effective for us
 on January&amp;#xA0;1, 2019. The Company is evaluating the impact the
 adoption of ASU No. 2016-02 will have on its consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In March 2016, the FASB issued ASU No.&amp;#xA0;2016-09,
 Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements to
 Employee Share-Based Payment Accounting. The new standard involves
 several aspects of the accounting for share-based payment
 transactions, including the income tax consequences, classification
 of awards as either equity or liabilities and classification on the
 statement of cash flows. For public business entities, the
 amendments in this standard are effective for annual periods
 beginning after December&amp;#xA0;15, 2016, and interim periods within
 those annual periods. The Company is evaluating the impact the
 adoption of ASU No. 2016-09 will have on its consolidated financial
 statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_78761DE4-AB25-4124-916A-4162479C7B25_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Property and equipment &amp;#x2014; net consist of the following (dollar
 amounts in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Useful&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Life&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Land&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,435&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,435&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Buildings&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39-40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Building improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5-40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60,584&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60,584&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Machinery and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3-15&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,761&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;68,434&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Furniture, fixtures and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5-10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Computer equipment and software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Construction in progress&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;437&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;167,440&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;168,262&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Less accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(120,018&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(119,513&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Property and equipment &amp;#x2014; net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;47,422&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,749&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Depreciation and amortization expense related to property and
 equipment for the three and six months ended June&amp;#xA0;30, 2016 and
 2015 was as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Depreciation and amortization expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;589&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,740&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,179&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,117&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_01EC0C49-011C-46D2-8446-492A0815B5B4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Inventories consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Raw materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,491&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Work-in-process&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,155&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finished goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total Inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_0A53B818-34D4-40B8-90FF-0D95CE4F7FD1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Lease payments to the Mann Foundation for the three and six months
 ended June&amp;#xA0;30, 2016 and 2015 were as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Lease payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;133&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="shares" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_13">442082000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_018F488E-3308-44E1-9111-8683B17B8567_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_7D7751EF-D6B9-4413-8474-FBEC2649ADED_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;13. Facility Agreement&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As of June&amp;#xA0;30, 2016, there were $60.0 million principal amount
 of 2019 notes and $20.0 million principal amount of Tranche&amp;#xA0;B
 notes outstanding. The 2019 notes accrue interest at an annual rate
 of 9.75% and the Tranche B notes accrue interest at an annual rate
 of 8.75%. The Facility Agreement principal repayment schedule is
 comprised of annual payments beginning on July&amp;#xA0;1, 2016 and
 ending December&amp;#xA0;9, 2019. The repayment dates correspond to the
 dates on which the 2019 notes or Tranche B notes, as applicable,
 were issued.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In conjunction with the Facility Agreement, the Company entered
 into a Milestone Rights Agreement with Deerfield which requires the
 Company to make contingent payments to Deerfield, totaling up to
 $90.0 million, upon the Company achieving specified
 commercialization milestones. The Milestone Rights were initially
 recorded as a short-term liability equal to $3.2 million included
 in accrued expenses and other current liabilities in the
 accompanying condensed consolidated balance sheet and a long-term
 liability equal to $13.1 million included in other liabilities. As
 of June&amp;#xA0;30, 2016, the remaining liability balance of $8.9
 million is classified as long-term liability in other
 liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Accretion of debt issuance cost and debt discount in connection
 with the Facility financing agreement during the three and six
 months ended June&amp;#xA0;30, 2016 and 2015 are as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion expense- debt issuance cost&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion expense- debt discount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;433&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;380&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;852&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;745&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Facility Agreement contains a financial covenant that requires
 the Company&amp;#x2019;s cash and cash equivalents, which include
 available borrowings under the Loan Arrangement, on the last day of
 each fiscal quarter to not be less than $25.0 million. The Company
 will need to raise additional capital to support its current
 operating plans. Due to the uncertainties related to maintaining
 sufficient resources to comply with the aforementioned covenant,
 the 2019 notes have been classified as current liabilities in the
 accompanying balance sheet as of June&amp;#xA0;30, 2016. In the event
 of non-compliance, Deerfield may declare all or any portion of the
 2019 notes and/or Tranche B notes to be immediately due and
 payable.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <dei:DocumentPeriodEndDate contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_7991201F-DF73-4876-9DEE-9BCF27629DC0_1_2">2016-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityFilerCategory contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_018F488E-3308-44E1-9111-8683B17B8567_1_400004">Large Accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_44917828-A045-4C82-8DBC-66ECF907811A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;3. Property and equipment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Property and equipment &amp;#x2014; net consist of the following (dollar
 amounts in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Useful&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Life&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Land&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,435&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,435&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Buildings&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39-40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Building improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5-40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60,584&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60,584&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Machinery and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3-15&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,761&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;68,434&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Furniture, fixtures and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5-10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Computer equipment and software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Construction in progress&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;437&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;167,440&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;168,262&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Less accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(120,018&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(119,513&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Property and equipment &amp;#x2014; net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;47,422&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,749&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The December&amp;#xA0;31, 2015 balances have been reclassified to the
 current year presentation by allocating the impairment of
 $140.4&amp;#xA0;million to the individual asset groups.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Depreciation and amortization expense related to property and
 equipment for the three and six months ended June&amp;#xA0;30, 2016 and
 2015 was as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Depreciation and amortization expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;589&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,740&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,179&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,117&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:RevenueRecognitionDeferredRevenue contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_764111BE-38F2-41CA-85C1-F3B27CD56AB2_1_0">&lt;div&gt;&lt;strong&gt;&lt;em&gt;&lt;font size="2"&gt;Deferred costs from
 collaboration&lt;/font&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#xA0;&amp;#x2014;
 Deferred costs from collaboration represent the costs of product
 manufactured and sold to Sanofi, as well as certain direct costs
 associated with a firm purchase commitment entered into in
 connection with the collaboration with Sanofi. Such costs are
 deferred to the extent they are deemed recoverable through the
 recognition of future revenue associated with the collaboration and
 will be amortized as the associated revenue is
 recognized.&lt;/div&gt;</us-gaap:RevenueRecognitionDeferredRevenue>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_20FAE826-0C96-4059-90DF-AFEDFDB08AB1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Total stock-based compensation expense recognized in the
 accompanying condensed consolidated statements of operations for
 the three and six months ended June&amp;#xA0;30, 2016 and 2015 was as
 follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &amp;quot;Times New Roman&amp;quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,355&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,778&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;
 &amp;#xA0;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_525F141E-05DD-426B-BC22-3F137D854677_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;14. Warrants&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In May 2016, the Company sold in a registered offering an aggregate
 of 48,543,687 shares of common stock together with A Warrants
 exercisable for up to an aggregate of 36,407,765 shares of common
 stock and B Warrants exercisable for up to an aggregate of
 12,135,921 shares of common stock with a total fair value of
 $44.7&amp;#xA0;million. Each of the warrants has an exercise price of
 $1.50 per share.&amp;#xA0;The A Warrants became exercisable upon
 issuance and will expire two years thereafter. The B Warrants will
 become exercisable beginning in May 2017 and will expire 30 months
 after the date of issuance.&amp;#xA0;The shares of common stock and the
 warrants are immediately separable and issued
 separately.&amp;#xA0;There have been no warrants exercised as of
 June&amp;#xA0;30, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The Company evaluated the A Warrants and B Warrants to determine
 the appropriate classification. The Company determined that the A
 Warrants require liability classification primarily due to a
 price-protection clause if certain dilutive financing occurs. The
 fair value of the A Warrants was recorded as warrant liability in
 the condensed consolidated balance sheet at issuance and is
 adjusted to fair value at each reporting period until exercise or
 expiration. The Company determined that the B Warrants met the
 criteria for equity classification and has accounted for such
 warrants in additional paid in capital.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 As of May&amp;#xA0;12, 2016 and June&amp;#xA0;30, 2016, the fair value of
 the A Warrants liability was $12.8 million and $18.1&amp;#xA0;million,
 respectively, and was estimated using a Monte Carlo valuation
 pricing model. The Company recognized a loss of $5.3 million to
 reflect the fair value adjustment of the A Warrant liability from
 the date of issuance, May 12, 2016 to June&amp;#xA0;30, 2016. As of
 May&amp;#xA0;12, 2016 the fair value of the B&amp;#xA0;Warrants at issuance
 was $5.0&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_12">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_BC8AC782-E7A9-4C6C-8346-9641AAF6225F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;10. Net loss per common share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Basic net loss per
 share excludes dilution for potentially dilutive securities and is
 computed by dividing net loss by the weighted average number of
 common shares outstanding during the period excluding the 9,000,000
 shares loaned to Bank of America under a share lending arrangement
 for periods prior to the third quarter of 2015. In the third
 quarter of 2015, the 9,000,000 shares loaned to Bank of America
 were returned and therefore do not impact the three or six months
 ended June 30, 2016. Prior to the return of those shares, the
 borrowed shares were not considered outstanding for the purpose of
 computing and reporting basic or diluted loss per share because the
 share borrower had to return all borrowed shares to the Company
 (or, in certain circumstances, the cash value thereof).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Diluted net loss per share reflects the potential dilution that
 could occur if securities or other contracts to issue common stock
 were exercised or converted into common stock. Potentially dilutive
 securities are excluded from the computation of diluted net loss
 per share for all of the periods presented in the accompanying
 condensed consolidated statements of operations because the
 reported net loss in each of these periods results in their
 inclusion being antidilutive. Antidilutive securities, which
 consist of stock options, restricted stock units, warrants, and
 shares that could be issued upon conversion of the senior
 convertible notes, are not included in the diluted net loss per
 share calculation and excluded the 9,000,000 shares of the
 Company&amp;#x2019;s common stock loaned under the share lending
 arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On February&amp;#xA0;8, 2016, all unexercised warrants related to the
 February 2012 public offering expired. In November 2015, the
 Company issued warrants to purchase 159,304 shares of the
 Company&amp;#x2019;s common stock to the placement agent in exchange for
 services related to the Company&amp;#x2019;s offering to select
 investment funds in Israel.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In May 2016, the Company issued Series A warrants (&amp;#x201C;A
 Warrants&amp;#x201D;) to purchase 36,407,765 shares of the
 Company&amp;#x2019;s common stock and Series B warrants (&amp;#x201C;B
 Warrants) to purchase 12,135,921 shares of the Company&amp;#x2019;s
 common stock to certain institutional investors.&amp;#xA0;These
 warrants remain outstanding at June&amp;#xA0;30, 2016 (see Note 14
 &amp;#x2013; Warrants).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Potentially dilutive securities outstanding are summarized as
 follows (in shares):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of common stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,219,831&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,985,768&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vesting of restricted stock units&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,553,757&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,198,173&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,702,990&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,090,013&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion of senior convertible notes into common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,072,809&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,708,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85,549,387&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,982,544&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <dei:EntityRegistrantName contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_018F488E-3308-44E1-9111-8683B17B8567_1_400001">MANNKIND CORP</dei:EntityRegistrantName>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_C15BE42A-4D5A-4ADA-95D2-F53AB81A9025_1_2">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_5AFF38F2-DFCE-4DC7-B1D6-0EBF1CE7E669_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;8. Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company applies various valuation approaches in determining the
 fair value of its financial assets and liabilities within a
 hierarchy that maximizes the use of observable inputs and minimizes
 the use of unobservable inputs by requiring that observable inputs
 be used when available. Observable inputs are inputs that market
 participants would use in pricing the asset or liability based on
 market data obtained from sources independent of the Company.
 Unobservable inputs are inputs that reflect the Company&amp;#x2019;s
 assumptions about the inputs that market participants would use in
 pricing the asset or liability and are developed based on the best
 information available in the circumstances. The fair value
 hierarchy is broken down into three levels based on the source of
 inputs as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Level 1&amp;#x2014; Quoted prices for identical instruments in active
 markets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Level 2&amp;#x2014; Quoted prices for similar instruments in active
 markets; quoted prices for identical or similar instruments in
 markets that are not active; and model-derived valuations whose
 inputs are observable or whose significant value drivers are
 observable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Level 3&amp;#x2014; Significant inputs to the valuation model are
 unobservable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The availability of observable inputs can vary among the various
 types of financial assets and liabilities. To the extent that the
 valuation is based on models or inputs that are less observable or
 unobservable in the market, the determination of fair value
 requires more judgment. In certain cases, the inputs used to
 measure fair value may fall into different levels of the fair value
 hierarchy. In such cases, for financial statement disclosure
 purposes, the level in the fair value hierarchy within which the
 fair value measurement is categorized is based on the lowest level
 input that is significant to the overall fair value
 measurement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Cash equivalents consist of highly liquid investments with original
 or remaining maturities of 90 days or less at the time of purchase,
 that are readily convertible into cash. As of June&amp;#xA0;30, 2016
 and December&amp;#xA0;31, 2015, the Company held $63.7 million and
 $59.1 million, respectively, of cash and cash equivalents,
 consisting primarily of money market funds of $56.8 million and
 $55.8 million, respectively, and the remaining in non-interest
 bearing checking accounts. The fair value of these money market
 funds was determined by using quoted prices for identical
 investments in an active market (Level 1 in the fair value
 hierarchy).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Related-Party Arrangement&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The fair value of the note payable to our principal stockholder
 cannot be reasonably estimated as the Company would not be able to
 obtain a similar credit arrangement in the current economic
 environment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Financial liabilities&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following tables set forth the fair value of our financial
 instruments (in millions):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;June&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Financial liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Senior convertible notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Facility financing obligation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Milestone rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Sanofi Loan Facility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total financial liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;197.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;197.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Financial liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Senior convertible notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Facility financing obligation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Milestone rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Sanofi Loan Facility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total financial liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Senior convertible notes&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The estimated fair value of the 2018 notes was calculated based on
 model-derived valuations whose inputs were observable, such as the
 Company&amp;#x2019;s stock price and yields on U.S. Treasury notes and
 actively traded bonds, and non-observable, such as the
 Company&amp;#x2019;s longer-term historical volatility, and estimated
 yields implied from any available market trades of the
 Company&amp;#x2019;s issued debt instruments. As there is no current
 active and observable market for the 2018 notes, the Company
 determined the estimated fair value using a convertible bond
 valuation model within a lattice framework. The convertible bond
 valuation model combined expected cash flows based on terms of the
 notes with market-based assumptions regarding risk-free rate,
 risk-adjusted yields (20%), stock price volatility (87.5%)&amp;#xA0;and
 recent price quotes and trading information regarding Company
 issued debt instruments and shares of common stock into which the
 notes are convertible (Level 3 in the fair value hierarchy).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Facility Agreement&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As discussed in Note&amp;#xA0;13 &amp;#x2014; Facility Agreement, in
 connection with the Facility Agreement, the Company issued 2019
 notes and subsequently issued Tranche B notes (the &amp;#x201C;Facility
 Financing Obligation&amp;#x201D;). As there is no current observable
 market for the 2019 notes or Tranche B notes, the Company
 determined the estimated fair value using a bond valuation model
 based on a discounted cash flow methodology. The bond valuation
 model combined expected cash flows associated with principal
 repayment and interest based on the contractual terms of the debt
 agreement discounted to present value using a selected market
 discount rate. On June&amp;#xA0;30, 2016 the market discount rate was
 recalculated at 11.0% for the 2019 notes and for the Tranche B
 notes, which reflected decline in the market price of benchmark
 U.S. Treasury securities as compared to prior measurement date
 (Level 3 in the fair value hierarchy).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In addition to the 2019 notes and Tranche B notes, the Company also
 issued certain rights to receive payments of up to $90.0 million
 upon occurrence of specified strategic and sales milestones (the
 &amp;#x201C;Milestone Rights&amp;#x201D;). These rights are not reflected in
 the facility financing obligation. The estimated fair value of the
 Milestone Rights was calculated using the income approach in which
 the cash flows associated with the specified contractual payments
 were adjusted for both the expected timing and the probability of
 achieving the milestones discounted to present value using a
 selected market discount rate (Level 3 in the fair value
 hierarchy). The expected timing and probability of achieving the
 milestones, starting in 2014, was developed with consideration
 given to both internal data, such as progress made to date and
 assessment of criteria required for achievement, and external data,
 such as market research studies. The discount rate (14.0%)&amp;#xA0;was
 selected based on an estimation of required rate of returns for
 similar investment opportunities using available market data. As of
 June&amp;#xA0;30, 2016, the carrying value of the Milestone Rights is
 $8.9 million, classified as a long-term liability in other
 liabilities and the fair value is estimated at
 $15.6&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Sanofi Loan Facility&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As discussed in Note&amp;#xA0;7 &amp;#x2014; Collaboration arrangement, the
 Sanofi Loan Facility consists of a senior secured revolving
 promissory note and a guaranty and security agreement with an
 affiliate of Sanofi which provides the Company with a secured loan
 facility of up to $175.0 million to fund the Company&amp;#x2019;s share
 of net losses under the Sanofi License Agreement. The estimated
 fair value was determined using a discounted cash flow model in
 which time outstanding and discount rate were primary variables.
 This method considered the key elements of the contractual terms of
 the Sanofi Loan Facility, market-based estimated cost of capital,
 and time value of money, namely the amount of time to settlement
 and the estimated discount rate (11%)&amp;#xA0;appropriate for the
 liability (Level 3 in the fair value hierarchy). As of
 June&amp;#xA0;30, 2016 the carrying value of the Sanofi Loan Facility
 is $70.3 million and the fair value is estimated at $62.0
 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Warrant liability&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Warrant liabilities are measured at fair value using a Monte Carlo
 pricing valuation model. The assumptions used in the valuation
 model for the common stock warrant liabilities were: (a) a
 risk-free interest rate based on the rates for U.S. Treasury
 zero-coupon bonds with maturities similar to those of the remaining
 contractual term of the warrants; (b) an assumed dividend yield of
 zero percent based on the Company&amp;#x2019;s expectation that it will
 pay no dividends in the foreseeable future; (c) an expected term
 based on the remaining contractual term of the warrants; and (d) an
 expected volatility based upon the Company&amp;#x2019;s historical
 volatility over the remaining contractual term of the warrants and
 probability of a dilutive financing that may trigger a price
 protection clause. The significant unobservable input used in
 measuring the fair value of the common stock warrant liabilities is
 the expected volatility. Significant increases in volatility would
 result in a higher fair value measurement. (Level 3 in the fair
 value hierarchy) See note 14 &amp;#x2013; Warrants for further
 discussion.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:LongTermDebtTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_771EEDA2-D9F6-47E3-AB66-A9E93DB47E06_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;6. Senior convertible notes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Senior convertible notes consist of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Senior Convertible notes&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Principal amount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unamortized premium&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;660&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unaccreted debt issuance costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net carrying amount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-LEFT: 75px; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Issuance of 5.75% Senior Convertible Subordinated Exchange Notes
 due 2018&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The 5.75% senior convertible notes due 2018 (the &amp;#x201C;2018
 notes&amp;#x201D;) are the Company&amp;#x2019;s general, unsecured, senior
 obligations, except that the 2018 notes are subordinated in right
 of payment to the outstanding notes issued pursuant to the Facility
 Agreement and the Company&amp;#x2019;s borrowings under the Sanofi Loan
 Facility with an affiliate of Sanofi. The 2018 notes rank equally
 in right of payment with the Company&amp;#x2019;s other unsecured senior
 debt. The 2018 notes bear interest at the rate of 5.75%&amp;#xA0;per
 year on the principal amount, payable semiannually in arrears in
 cash on February&amp;#xA0;15 and August&amp;#xA0;15 of each year, beginning
 February&amp;#xA0;15, 2016, with interest accruing from August&amp;#xA0;15,
 2015. The 2018 notes mature on August&amp;#xA0;15, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The 2018 notes are convertible, at the option of the holder, at any
 time on or prior to the close of business on the business day
 immediately preceding the stated maturity date, into shares of the
 Company&amp;#x2019;s common stock at an initial conversion rate of
 147.0859 shares per $1,000 principal amount of 2018 notes, which is
 equal to a conversion price of approximately $6.80 per share, the
 same conversion price as that of the 2015 notes on the date of
 exchange. The conversion rate is subject to adjustment under
 certain circumstances described in an indenture governing the 2018
 notes dated August&amp;#xA0;10, 2015 with US Bank (as successor trustee
 to Wells Fargo, National Association), including in connection with
 a make-whole fundamental change. If certain fundamental changes
 occur, such as share price being over $4.82 on date of conversion,
 the Company will be obligated to pay a make-whole premium on any
 2018 notes converted in connection with such fundamental change by
 increasing the conversion rate on such 2018 notes. In such
 instances, the amount of the fundamental change make-whole premium
 will be based on the Company&amp;#x2019;s common stock price and the
 effective date of the applicable fundamental change. The Company
 can force conversion at $6.80 or 747.1 thousand shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 If the Company undergoes certain fundamental changes, except in
 certain circumstances, each holder of 2018 notes will have the
 option to require the Company to repurchase all or any portion of
 that holder&amp;#x2019;s 2018 notes. The fundamental change repurchase
 price will be 100% of the principal amount of the 2018 notes to be
 repurchased plus accrued and unpaid interest, if any.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On or after the date that is one year following the original issue
 date of the 2018 notes, the Company will have the right to redeem
 for cash all or part of the 2018 notes if the last reported sale
 price of its common stock exceeds 130% of the conversion price then
 in effect for 20 or more trading days during the 30 consecutive
 trading day period ending on the trading day immediately prior to
 the date of the redemption notice. The redemption price will equal
 the sum of 100% of the principal amount of the 2018 notes to be
 redeemed, plus accrued and unpaid interest. Under the terms of the
 indenture, the conversion option can be net-share settled and the
 maximum number of shares that could be required to be delivered
 under the indenture, including the make-whole shares, is fixed and
 less than the number of authorized and unissued shares less the
 maximum number of shares that could be required to be delivered
 during the term of the 2018 notes under existing commitments.
 Applying the Company&amp;#x2019;s sequencing policy, the Company
 performed an analysis at the time of the offering of the 2018 notes
 and each reporting date since and has concluded that the number of
 available authorized shares at the time of the offering and each
 subsequent reporting date was sufficient to deliver the number of
 shares that could be required to be delivered during the term of
 the 2018 notes under existing commitments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The 2018 notes provide that upon an acceleration of certain
 indebtedness, including the 9.75% Senior Convertible Notes due 2019
 (the &amp;#x201C;2019 notes&amp;#x201D;) and the 8.75% Senior Convertible
 Notes due 2019 (the &amp;#x201C;Tranche B notes&amp;#x201D;) issued to
 Deerfield pursuant to the Facility Agreement (see Note
 13&amp;#xA0;&amp;#x2014;&amp;#xA0;Facility Agreement), the holders may elect to
 accelerate the Company&amp;#x2019;s repayment obligations under the
 notes if such acceleration is not cured, waived, rescinded or
 annulled. There can be no assurance that the holders would not
 choose to exercise these rights in the event such events were to
 occur.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company incurred approximately $0.8 million in issuance costs
 which are recorded as an offset to the 2018 notes in the
 accompanying condensed consolidated balance sheets. These costs are
 being accreted to interest expense using the effective interest
 method over the term of the 2018 notes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Accretion of debt issuance expense in connection with the 2018
 notes during the three and six months ended June&amp;#xA0;30, 2016 were
 $64,000 and $126,000, respectively, and there was no accretion of
 debt issuance expense in connection with the 2018 notes during the
 three and six months ended June&amp;#xA0;30, 2015.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_62DA4FC9-C761-404D-96ED-D5A86226C2DA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;5. Related-party arrangements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In October 2007, the Company entered into a $350.0 million loan
 arrangement with its principal stockholder. The Mann Group Loan
 Arrangement has been amended from time to time. On October&amp;#xA0;31,
 2013, the promissory note underlying The Mann Group Loan
 Arrangement was amended to, among other things, extend the maturity
 date of the loan to January&amp;#xA0;5, 2020, extend the date through
 which the Company can borrow under The Mann Group Loan Arrangement
 to December&amp;#xA0;31, 2019, increase the aggregate borrowing amount
 under The Mann Group Loan Arrangement from $350.0 million to $370.0
 million and provide that repayments or cancellations of principal
 under The Mann Group Loan Arrangement will not be available for
 reborrowing.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 As of June&amp;#xA0;30, 2016, the total principal amount outstanding
 under The Mann Group Loan Arrangement was $49.5 million, and the
 amount available for future borrowings was $30.1 million. Interest,
 at a fixed rate of 5.84%, is due and payable quarterly in arrears
 on&amp;#xA0;the first day of each calendar quarter for the preceding
 quarter, or at such other time as the Company and The Mann Group
 mutually agree. All or any portion of accrued and unpaid interest
 that becomes due and payable may be paid-in-kind and capitalized as
 additional borrowings at any time and would be classified as
 non-current upon mutual agreement of both parties. As of
 June&amp;#xA0;30, 2016, the Company had accrued $7.8 million of
 interest in other long term liabilities. The Mann Group can require
 the Company to prepay up to $200.0 million in advances that have
 been outstanding for at least 12 months (less approximately $105.0
 million aggregate principal amount that has been cancelled in
 connection with two common stock purchase agreements). If The Mann
 Group exercises this right, the Company will have 90 days after The
 Mann Group provides written notice (or the number of days to
 maturity of the note if less than 90&amp;#xA0;days) to prepay such
 advances. However, pursuant to a letter agreement entered into in
 August 2010, The Mann Group has agreed to not require the Company
 to prepay amounts outstanding under the amended and restated
 promissory note if the prepayment would require the Company to use
 its working capital resources. The Mann Group entered into a
 subordination agreement with Deerfield pursuant to which The Mann
 Group agreed with Deerfield not to demand or accept any payment
 under The Mann Group Loan Arrangement until the Company&amp;#x2019;s
 payment obligations to Deerfield under the Facility Agreement have
 been satisfied in full. Subject to the foregoing, in the event of a
 default under The Mann Group Loan Arrangement, all unpaid principal
 and interest either becomes immediately due and payable or may be
 accelerated at The Mann Group&amp;#x2019;s option, and the interest rate
 will increase to the one-year LIBOR calculated on the date of the
 initial advance or in effect on the date of default, whichever is
 greater, plus 5%&amp;#xA0;per annum. All borrowings under The Mann
 Group Loan Arrangement are unsecured. The Mann Group Loan
 Arrangement contains no financial covenants.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During the six months ended June&amp;#xA0;30, 2016, there were no
 additional borrowings under or amendments to The Mann Group Loan
 Arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In May 2015, the Company entered into a sublease agreement with the
 Alfred Mann Foundation for Scientific Research (the &amp;#x201C;Mann
 Foundation&amp;#x201D;), a California not-for-profit corporation. The
 lease is for approximately 12,500 square feet of office space in
 Valencia, California and expires in April 2017. The office space
 contains the Company&amp;#x2019;s principal executive offices.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Lease payments to the Mann Foundation for the three and six months
 ended June&amp;#xA0;30, 2016 and 2015 were as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Lease payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;133&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company has entered into indemnification agreements with each
 of its directors and executive officers, in addition to the
 indemnification provided for in its amended and restated
 certificate of incorporation and amended and restated bylaws (see
 Note&amp;#xA0;11&amp;#xA0;&amp;#x2014;&amp;#xA0;Commitments and contingencies).&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_9A344940-9500-41EB-890E-AF7BD6861737_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Accrued expenses and other current liabilities consist of the
 following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Salary and related expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,536&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,662&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Construction in progress&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,414&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued expenses and other current liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,252&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,929&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:SalesRevenueNet contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_0">0</us-gaap:SalesRevenueNet>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_28">1144000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_34">2678000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0DBC9591-D373-40CA-9E57-52462361A9EB_3_2">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_14">-23000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_6">-39136000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_11">-54831000</us-gaap:NetIncomeLoss>
  <us-gaap:LoansAssumed1 contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_46">5003000</us-gaap:LoansAssumed1>
  <us-gaap:InterestPaidNet contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_44">4608000</us-gaap:InterestPaidNet>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_17">238000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_13">2866000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0DBC9591-D373-40CA-9E57-52462361A9EB_3_4">-54832000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_38">3000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_10">41000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_7">-5892000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_11">-717000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0DBC9591-D373-40CA-9E57-52462361A9EB_3_3">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_15">-2595000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0D920E6C-6368-43EE-9362-B44DAB6E09F6_3_0">2628000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6341079E-0A0E-40E2-BC86-72199EC7DC79_3_0">1179000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ForeignCurrencyTransactionLossBeforeTax contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_7">2023000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
  <us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_22">9202000</us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_19">2663000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_18">-12532000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_30">-1127000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_29">17000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_8">1443000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_4">2628000</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_3">2058000</us-gaap:DepreciationAndAmortization>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_8">5306000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_21">177000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:PaidInKindInterest contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_5">2604000</us-gaap:PaidInKindInterest>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_33">50000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_2">9440000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_3">18460000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_5">39136000</us-gaap:CostsAndExpenses>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_9">8401000</us-gaap:InterestExpenseDebt>
  <us-gaap:ManufacturingCosts contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_3_4">11236000</us-gaap:ManufacturingCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_39">48053000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_40">4659000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <mnkd:LongtermPurchaseCommitmentRenewalTimePeriod contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_E03E6754-A362-4F02-9D52-9B78EF064823_1_1">P2Y</mnkd:LongtermPurchaseCommitmentRenewalTimePeriod>
  <mnkd:LossesOnPurchaseCommitments contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="0" id="id_8322447_53734037-3993-4303-B9C6-8664395CE91D_3_10">74000</mnkd:LossesOnPurchaseCommitments>
  <mnkd:BasisOfPresentationPolicyTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_6ADE76B5-B5AD-4E18-AADA-D5CA0511AFAB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&amp;#xA0;&lt;/i&gt;&lt;/b&gt;&amp;#x2014; The
 Company&amp;#x2019;s primary activities since incorporation have been
 establishing its facilities, recruiting personnel, conducting
 research and development, business development, business and
 financial planning, raising capital, and commercial manufacturing.
 In addition, the Company recently commenced commercial sales and
 marketing activities related to Afrezza. It is costly to develop
 and conduct clinical studies for therapeutic products, as well as
 to establish and maintain commercial sales and marketing
 capabilities. As of June&amp;#xA0;30, 2016, the Company had an
 accumulated deficit of $2.9 billion and has reported negative cash
 flow from operations since inception, other than for the nine
 months ended September&amp;#xA0;30, 2014, the year ended
 December&amp;#xA0;31, 2014, and for the three months ended
 March&amp;#xA0;31, 2015, as a result of receipt of the upfront payment
 and milestone payments from Sanofi-Aventis U.S. LLC
 (&amp;#x201C;Sanofi&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In May 2016, pursuant to a previously filed Form S-3 Registration
 Statement, which was declared effective by the SEC on
 April&amp;#xA0;27, 2016, the Company sold in an underwritten public
 offering 48,543,692 shares of its common stock, together with
 warrants to purchase up to 48,543,692 shares of the Company&amp;#x2019;s
 common stock. Net proceeds from this offering were approximately
 $47.4&amp;#xA0;million after deducting discounts and commissions to the
 underwriters and paying for offering expenses, excluding any future
 proceeds from the exercise of the warrants. (see Note 14 &amp;#x2014;
 Warrants).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 At June&amp;#xA0;30, 2016, the Company&amp;#x2019;s capital resources
 consisted of cash and cash equivalents of $63.7 million. The
 Company expects to continue to incur significant expenditures to
 support commercial manufacturing and sales and marketing of Afrezza
 and the development of other product candidates. The facility
 agreement (the &amp;#x201C;Facility Agreement&amp;#x201D;) with Deerfield
 Private Design Fund II, L.P. (&amp;#x201C;Deerfield Private Design
 Fund&amp;#x201D;) and Deerfield Private Design International II, L.P.
 (collectively, &amp;#x201C;Deerfield&amp;#x201D;) and the First Amendment to
 Facility Agreement and Registration Rights Agreement (the
 &amp;#x201C;First Amendment&amp;#x201D;) that resulted in additional sales of
 an additional tranche of notes (see Note
 13&amp;#xA0;&amp;#x2014;&amp;#xA0;Facility Agreement) requires the Company to
 maintain at least $25.0 million in cash and cash equivalents or
 available borrowings under the loan arrangement, dated as of
 October&amp;#xA0;2, 2007, between The Company and The Mann Group LLC
 (as amended, restated, or otherwise modified as of the date hereof,
 &amp;#x201C;The Mann Group Loan Arrangement&amp;#x201D;), as of the last day
 of each fiscal quarter. The Company will need to continue to incur
 expenses for the commercialization of Afrezza and will need to
 raise additional capital to finance such activities. The Company
 cannot be certain that it will be able to raise additional capital
 on favorable terms, or at all, which raises substantial doubt about
 the Company&amp;#x2019;s ability to continue as a going concern. The
 financial statements do not include any adjustments that might
 result from the outcome of this uncertainty.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On August&amp;#xA0;11, 2014, the Company executed a license and
 collaboration agreement (the &amp;#x201C;Sanofi License
 Agreement&amp;#x201D;) with Sanofi-Aventis Deutschland GmbH (which
 subsequently assigned its rights and obligations under the
 agreement to Sanofi), pursuant to which Sanofi was responsible for
 global commercial, regulatory and development activities for
 Afrezza. The Sanofi License Agreement became effective on
 September&amp;#xA0;23, 2014. The Company manufactured Afrezza at its
 manufacturing facility in Danbury, Connecticut to supply
 Sanofi&amp;#x2019;s demand for the product pursuant to a supply
 agreement dated August&amp;#xA0;11, 2014 (the &amp;#x201C;Sanofi Supply
 Agreement&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The Sanofi License Agreement and Sanofi Supply Agreement
 terminated, effective April 4, 2016, following which the Company
 assumed responsibility for the worldwide development and
 commercialization of Afrezza from Sanofi. Under the terms of the
 transition agreement, Sanofi continued to fulfill orders for
 Afrezza in the United States until the Company began distributing
 MannKind-branded product to major wholesalers during the week of
 July 25, 2016. The Company expects to commence recognition, likely
 within the third quarter of 2016, the deferred sales from
 collaboration, deferred costs from collaboration, and deferred
 payments from collaboration deferred as of June&amp;#xA0;30, 2016, as a
 result of the termination of the transition agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Under the Sanofi License Agreement, worldwide profits and losses,
 which are determined based on the difference between the net sales
 of Afrezza and the costs and expenses incurred by the Company and
 Sanofi that are specifically attributable or related to the
 development, regulatory filings, manufacturing, or
 commercialization of Afrezza, are shared 65% by Sanofi and 35% by
 the Company until Sanofi ceases to distribute Afrezza. As a result
 of this loss share provision, and because the Company does not
 currently have the ability to estimate the amount of costs that
 would potentially be incurred related to the Sanofi License
 Agreement, the amount of up-front cash payment or milestone
 payments that could be recognized as revenue is not fixed or
 determinable. In connection with the Sanofi License Agreement, an
 affiliate of Sanofi provided the Company with a secured loan
 facility (the &amp;#x201C;Sanofi Loan Facility&amp;#x201D;) of up to $175.0
 million to fund the Company&amp;#x2019;s share of net losses under the
 Sanofi License Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Additional funding sources that are, or in certain circumstances
 may be, available to the Company, include approximately $30.1
 million principal amount of available borrowings under The Mann
 Group Loan Arrangement. A portion of these available borrowings may
 be used to capitalize accrued interest into principal, upon mutual
 agreement of the parties, as it becomes due and payable under The
 Mann Group Loan Arrangement (see Note
 5&amp;#xA0;&amp;#x2014;&amp;#xA0;Related-party arrangements). The Company cannot
 provide assurances that its plans will not change or that changed
 circumstances will not result in the depletion of its capital
 resources more rapidly than it currently anticipates. The Company
 is seeking and will need to raise additional capital, whether
 through a sale of equity or debt securities, a strategic business
 collaboration with a pharmaceutical company, the establishment of
 other funding facilities, licensing arrangements, asset sales or
 other means, in order to continue the development and
 commercialization of Afrezza and other product candidates and to
 support its other ongoing activities. However, the Company cannot
 provide assurances that such additional capital will be available
 on acceptable terms or at all.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Certain prior year balances in the Statement of Cash Flows have
 been reclassified to conform to current year presentation.
 Specifically Interest incurred through borrowing under Sanofi Loan
 Facility and interest on note payable to principal stockholder have
 been reclassified from Accrued and other current liabilities and
 Other liabilities, respectively.&lt;/p&gt;
 &lt;/div&gt;</mnkd:BasisOfPresentationPolicyTextBlock>
  <mnkd:ClassOfWarrantOrRightExercised contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="shares" decimals="INF" id="id_8322447_4BEA620A-A767-4AC8-9844-4A68E275984E_2_8">0</mnkd:ClassOfWarrantOrRightExercised>
  <mnkd:BusinessPolicyTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_1FCC01EE-141B-4CCD-8434-4F12F9D1FE0D_1_0">&lt;div&gt;&lt;strong&gt;&lt;em&gt;&lt;font size="2"&gt;Business
 &amp;#x2014;&lt;/font&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#xA0;MannKind
 is a biopharmaceutical company focused on the discovery,
 development and commercialization of therapeutic products for
 diseases such as diabetes. Our only approved product, Afrezza
 (insulin human) inhalation powder, is a rapid-acting inhaled
 insulin that was approved by the U.S. Food and Drug Administration
 (the &amp;#x201C;FDA&amp;#x201D;) on June&amp;#xA0;27, 2014 to improve glycemic
 control in adult patients with diabetes.&lt;/div&gt;</mnkd:BusinessPolicyTextBlock>
  <mnkd:WarrantsPolicyTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_EECFE9C4-5A8C-43DB-8ED7-34CC397E9EAE_1_0">&lt;p&gt;&lt;strong&gt;&lt;em&gt;&lt;font size="2"&gt;Warrants&lt;/font&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#xA0;&amp;#x2014;
 The Company accounts for its warrants as either equity or
 liabilities based upon the characteristics and provisions of each
 instrument and evaluation. Warrants classified as derivative
 liabilities are recorded on the Company&amp;#x2019;s balance sheet at
 their fair value on the date of issuance and are of sufficient
 authorized shares available to satisfy the obligations are revalued
 at each subsequent balance sheet date, with fair value changes
 recognized as increases or deductions to other income (expense) in
 the statement of operations. The Company estimates the fair value
 of its derivative liabilities using third party valuation analysis
 that utilizes option pricing models and assumptions that are based
 on the individual characteristics of the warrants or instruments on
 the valuation date, as well as assumptions expected volatility,
 expected life, yield, and risk-free interest rate. Warrants
 classified as equity are recorded within additional paid in capital
 at the issuance date and are not remeasured in subsequent periods,
 unless the underlying assumptions change to trigger liability
 accounting.&lt;/p&gt;</mnkd:WarrantsPolicyTextBlock>
  <mnkd:LongTermPurchaseCommitmentExpirationDate contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_E03E6754-A362-4F02-9D52-9B78EF064823_1_0">2019-12-31</mnkd:LongTermPurchaseCommitmentExpirationDate>
  <mnkd:LongTermPurchaseCommitmentCancellationFees contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-5" id="id_8322447_53734037-3993-4303-B9C6-8664395CE91D_3_6">5200000</mnkd:LongTermPurchaseCommitmentCancellationFees>
  <mnkd:LongTermPurchaseCommitmentAmountPurchased contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_EUR" decimals="-5" id="id_8322447_53734037-3993-4303-B9C6-8664395CE91D_4_9">3400000</mnkd:LongTermPurchaseCommitmentAmountPurchased>
  <mnkd:RecentlyIssuedAccountingStandardsPolicyTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_D273F1B4-5EC3-47BD-A3B7-BFFDC804326C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Recently Issued Accounting Standards
 &amp;#x2014;&lt;/i&gt;&lt;/b&gt;&amp;#xA0;From time to time, new
 accounting pronouncements are issued by the Financial Accounting
 Standards Board (FASB) or other standard setting bodies that are
 adopted by the Company as of the specified effective date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In May 2014, the FASB issued ASU No. 2014-09 related to revenue
 recognition, which requires an entity to recognize the amount of
 revenue to which it expects to be entitled for the transfer of
 promised goods or services to customers. The standard requires a
 company to recognize revenue to depict the transfer of goods or
 services to customers in an amount that reflects the consideration
 it expects to be entitled to receive in exchange for those goods or
 services. In August 2015, the FASB issued ASU 2015-14, Revenue from
 Contracts with Customers (Topic 606): Deferral of the Effective
 Date, which delayed the effective date of the new standard from
 January&amp;#xA0;1, 2017 to January&amp;#xA0;1, 2018. The FASB also agreed
 to allow entities to choose to adopt the standard as of the
 original effective date. In March 2016, the FASB issued ASU
 No.&amp;#xA0;2016-08, Revenue from Contracts with Customers (Topic
 606): Principal versus Agent Considerations, which clarifies the
 implementation guidance on principal versus agent considerations.
 In April 2016, the FASB issued ASU No. 2016-10, Revenue from
 Contracts with Customers (Topic 606): Identifying Performance
 Obligations and Licensing, which clarifies certain aspects of
 identifying performance obligations and licensing implementation
 guidance.&amp;#xA0;In May 2016, the FASB issued ASU No. 2016-12,
 Revenue from Contracts with Customers (Topic 606): Narrow-Scope
 Improvements and Practical Expedients related to disclosures of
 remaining performance obligations, as well as other amendments to
 guidance on collectability, non-cash consideration and the
 presentation of sales and other similar taxes collected from
 customers.&amp;#xA0;The Company is assessing the potential impact of
 the new standards on its consolidated financial statements and has
 not yet selected a method of adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In August 2014, the FASB issued ASU No. 2014-15, which provides
 guidance on determining when and how reporting entities must
 disclose going-concern uncertainties in their financial statements.
 The new standard requires management to perform interim and annual
 assessments of an entity&amp;#x2019;s ability to continue as a going
 concern within one year of the date of issuance of the
 entity&amp;#x2019;s financial statements (or within one year after the
 date on which the financial statements are available to be issued,
 when applicable). Further, an entity must provide certain
 disclosures if there is &amp;#x201C;substantial doubt about the
 entity&amp;#x2019;s ability to continue as a going concern.&amp;#x201D; The
 ASU is effective for annual periods ending after December&amp;#xA0;15,
 2016, and interim periods thereafter; early adoption is permitted.
 The Company is evaluating the impact the adoption of ASU No.
 2014-15 will have on its consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic
 330): Simplifying the Measurement of Inventory. Topic 330,
 Inventory, currently requires an entity to measure inventory at the
 lower of cost or market. Market could be replacement cost, net
 realizable value, or net realizable value less an approximately
 normal profit margin. The amendments do not apply to inventory that
 is measured using last-in, first-out (LIFO) or the retail inventory
 method. The amendments apply to all other inventory, which includes
 inventory that is measured using first-in, first-out (FIFO) or
 average cost. The amendments are effective for fiscal years
 beginning after December&amp;#xA0;15, 2016, including interim periods
 within those fiscal years. The amendments should be applied
 prospectively with earlier application permitted as of the
 beginning of an interim or annual reporting period. The Company is
 evaluating the impact the adoption of ASU No. 2015-11 will have on
 its consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In January 2016, the FASB issued ASU No. 2016-01, Financial
 Instruments &amp;#x2014; Overall (Subtopic 825-10): Recognition and
 Measurement of Financial Assets and Financial Liabilities. The
 update is intended to improve the recognition and measurement of
 financial instruments. The ASU affects public and private
 companies, not-for-profit organizations, and employee benefit plans
 that hold financial assets or owe financial liabilities. The
 standard is effective for fiscal years beginning after
 December&amp;#xA0;15, 2017, including interim periods within those
 fiscal years. The Company is evaluating the impact the adoption of
 ASU No. 2016-01 will have on its consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In February 2016, the FASB issued ASU No.&amp;#xA0;2016-02, Leases
 (Topic 842). The new standard requires that all lessees recognize
 the assets and liabilities that arise from leases on the balance
 sheet and disclose qualitative and quantitative information about
 its leasing arrangements. The new standard will be effective for us
 on January&amp;#xA0;1, 2019. The Company is evaluating the impact the
 adoption of ASU No. 2016-02 will have on its consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 In March 2016, the FASB issued ASU No.&amp;#xA0;2016-09,
 Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements to
 Employee Share-Based Payment Accounting. The new standard involves
 several aspects of the accounting for share-based payment
 transactions, including the income tax consequences, classification
 of awards as either equity or liabilities and classification on the
 statement of cash flows. For public business entities, the
 amendments in this standard are effective for annual periods
 beginning after December&amp;#xA0;15, 2016, and interim periods within
 those annual periods. The Company is evaluating the impact the
 adoption of ASU No. 2016-09 will have on its consolidated financial
 statements.&lt;/p&gt;
 &lt;/div&gt;</mnkd:RecentlyIssuedAccountingStandardsPolicyTextBlock>
  <mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_32">734000</mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
  <mnkd:ScheduleOfAmortizationOfDebtIssuanceCostAndDebtDiscountTableTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_3F917045-8EBC-4347-A088-8C4D25C96DD3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Accretion of debt issuance cost and debt discount in connection
 with the Facility financing agreement during the three and six
 months ended June&amp;#xA0;30, 2016 and 2015 are as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion expense- debt issuance cost&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion expense- debt discount&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;433&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;380&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;852&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;745&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mnkd:ScheduleOfAmortizationOfDebtIssuanceCostAndDebtDiscountTableTextBlock>
  <mnkd:LossOnPurchaseCommitmentsPolicyPolicyTextBlock contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" id="id_8322447_F2D2C3DE-7521-4DE5-9971-9141F82FF37F_1_0">&lt;div&gt;&lt;strong&gt;&lt;em&gt;&lt;font size="2"&gt;Loss on purchase
 commitments&lt;/font&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#xA0;&lt;b style="FONT-SIZE: 13px; FONT-FAMILY: &apos;Times New Roman&apos;; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT-STYLE: normal; WIDOWS: 1; LETTER-SPACING: normal; LINE-HEIGHT: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;&lt;i&gt;&amp;#x2014;&lt;/i&gt;&lt;/b&gt;&amp;#xA0;The
 Company assesses whether losses on long term purchase commitments
 should be accrued. Losses that are expected to arise from firm,
 non-cancellable, commitments for the future purchases of inventory
 items are recognized unless recoverable through firm sales
 contracts. When making the assessment, the Company considers
 whether it is able to renegotiate with its vendors and considering
 the Company&amp;#x2019;s lower of cost or market analysis.&lt;/div&gt;</mnkd:LossOnPurchaseCommitmentsPolicyPolicyTextBlock>
  <mnkd:WarrantIssuanceCosts contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_9">653000</mnkd:WarrantIssuanceCosts>
  <mnkd:IncreaseDecreaseInPurchaseCommitmentLossCurrent contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_23">8312000</mnkd:IncreaseDecreaseInPurchaseCommitmentLossCurrent>
  <mnkd:IncreaseDecreaseInPurchaseCommitmentLossNoncurrent contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_24">-12204000</mnkd:IncreaseDecreaseInPurchaseCommitmentLossNoncurrent>
  <mnkd:ReclassificationOfDeferredCostsFromLossOnPurchaseCommitmentToDeferredCostsFromCollaboration contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_47">9202000</mnkd:ReclassificationOfDeferredCostsFromLossOnPurchaseCommitmentToDeferredCostsFromCollaboration>
  <mnkd:InterestOnNotePayableToPrincipalStockholder contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_BD5D7B43-390B-43FA-84E0-9186F986FE15_1_10">1443000</mnkd:InterestOnNotePayableToPrincipalStockholder>
  <us-gaap:FairValueInputsDiscountRate contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324497x1387193_1324896x1324925_1327094x1325206_1328615x1466792" unitRef="pure" decimals="3" id="id_8322447_9E561ADA-567B-4D9E-9849-1E0E3FBB63F3_1001_1">0.110</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324497x1494756_1324896x1324925_1327094x1325206" unitRef="pure" decimals="3" id="id_8322447_92EE771F-5032-4C78-85AB-E592AC06C213_1001_0">0.140</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324529x1373094" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E88BDEA2-16AC-439A-9986-152F9395BFAD_1002_0">126000000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:FairValueInputsDiscountRate contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324896x1324925_1325994x1469303_1327094x1325206" unitRef="pure" decimals="2" id="id_8322447_F82EF991-3FC1-4066-B71E-204DE9CC5CF7_1001_3">0.11</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324896x1324925_1327094x1325206_1328615x1466792" unitRef="pure" decimals="3" id="id_8322447_9E561ADA-567B-4D9E-9849-1E0E3FBB63F3_2001_0">0.110</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324896x1324925_1327094x1328686_1328615x1373094_1334317x1324465" unitRef="pure" decimals="3" id="id_8322447_F2530700-1A49-45CB-A6CD-7C5AD93F6FD3_1001_1">0.875</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324896x1324925_1327094x1328686_1328615x1373094_1334317x1324465" unitRef="pure" decimals="2" id="id_8322447_F2530700-1A49-45CB-A6CD-7C5AD93F6FD3_1001_0">0.20</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1367294_1326002x1335383" id="id_8322447_86981D09-EC2E-4A11-8D33-54F423FFF3B4_1003_1">2020-01-05</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1441734_1326002x1454078" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E006D4E8-8B23-4465-A73B-3D7CDAF2205D_1003_0">133000</us-gaap:LeaseAndRentalExpense>
  <mnkd:LeaseExpirationMonthYear contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1441734_1326002x1454078" id="id_8322447_95291E5A-DAAB-421D-90CC-358FCB06C122_1002_1">2017-04</mnkd:LeaseExpirationMonthYear>
  <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1444803_1326002x1365453" id="id_8322447_11F0D948-8392-4B5D-9B01-E333CD65232B_1001_9">The interest rate will increase to the one-year LIBOR calculated on the date  of the initial advance or in effect on the date of default, whichever is  greater, plus 5% per annum.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1444803_1326002x1365453_1333456x1331776" unitRef="pure" decimals="2" id="id_8322447_11F0D948-8392-4B5D-9B01-E333CD65232B_2001_8">0.05</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1469303_1327036x1425803" unitRef="iso4217_USD" decimals="-5" id="id_8322447_B29FCC3D-C2BC-4E5D-AFF2-9EF7C0655A75_1001_1">70300000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:PaidInKindInterest contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1469303_1327036x1425803" unitRef="iso4217_USD" decimals="-5" id="id_8322447_B29FCC3D-C2BC-4E5D-AFF2-9EF7C0655A75_1001_4">4300000</us-gaap:PaidInKindInterest>
  <mnkd:ProfitLossSharingAgreementAllocationPercentage contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1469303_1327036x1425803" unitRef="pure" decimals="2" id="id_8322447_852D2E04-1243-4845-B8A0-410708DEDBA5_1001_0">0.65</mnkd:ProfitLossSharingAgreementAllocationPercentage>
  <mnkd:CollaborationAgreementsExpirationDate contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1469303_1327036x1425803" id="id_8322447_D730AED8-D930-4936-85B7-FF6C81132E54_1002_1">2016-04-04</mnkd:CollaborationAgreementsExpirationDate>
  <mnkd:LossSharingAgreementAmount contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1469303_1327036x1425803_1327271x1443229" unitRef="iso4217_USD" decimals="-5" id="id_8322447_B29FCC3D-C2BC-4E5D-AFF2-9EF7C0655A75_2001_0">70000000</mnkd:LossSharingAgreementAmount>
  <mnkd:RelatedPartyTransactionPrepaymentPeriod contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1500563_1326002x1335383" id="id_8322447_11F0D948-8392-4B5D-9B01-E333CD65232B_3001_6">P90D</mnkd:RelatedPartyTransactionPrepaymentPeriod>
  <mnkd:AvailableLoanBalanceCancelled contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1500563_1326002x1335383" unitRef="iso4217_USD" decimals="-5" id="id_8322447_11F0D948-8392-4B5D-9B01-E333CD65232B_3001_7">105000000</mnkd:AvailableLoanBalanceCancelled>
  <mnkd:RelatedPartyTransactionDebtInstrumentPrepayment contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1500563_1326002x1335383_1335482x1328677" unitRef="iso4217_USD" decimals="INF" id="id_8322447_11F0D948-8392-4B5D-9B01-E333CD65232B_4001_4">200000000</mnkd:RelatedPartyTransactionDebtInstrumentPrepayment>
  <mnkd:NumberOfMonthsAdvancesOutstanding contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1500563_1326002x1335383_1335482x1331874" id="id_8322447_11F0D948-8392-4B5D-9B01-E333CD65232B_5001_5">P12M</mnkd:NumberOfMonthsAdvancesOutstanding>
  <mnkd:ProfitLossSharingAgreementAllocationPercentage contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1327036x1425803" unitRef="pure" decimals="2" id="id_8322447_852D2E04-1243-4845-B8A0-410708DEDBA5_2001_1">0.35</mnkd:ProfitLossSharingAgreementAllocationPercentage>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1328480x1426352" id="id_8322447_BD340945-D21E-4216-AB80-A6CC8E5E8033_1001_4">2016-07-01</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_8322447_1CA604D8-267A-4D12-BC8D-7F080DD021ED_1003_1">852000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_8322447_1CA604D8-267A-4D12-BC8D-7F080DD021ED_1003_0">17000</us-gaap:AmortizationOfFinancingCosts>
  <mnkd:DebtInstrumentDateOfLastRequiredPayment contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1328480x1426352" id="id_8322447_BD340945-D21E-4216-AB80-A6CC8E5E8033_1001_5">2019-12-09</mnkd:DebtInstrumentDateOfLastRequiredPayment>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1333589x1324465" unitRef="shares" decimals="0" id="id_8322447_1D988D42-E495-499A-9A8B-7224F9A5B992_1001_3">4072809</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1333589x1331109" unitRef="shares" decimals="0" id="id_8322447_1D988D42-E495-499A-9A8B-7224F9A5B992_2001_0">28219831</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1333589x1332392" unitRef="shares" decimals="0" id="id_8322447_1D988D42-E495-499A-9A8B-7224F9A5B992_3001_1">4553757</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1333589x1336129" unitRef="shares" decimals="0" id="id_8322447_1D988D42-E495-499A-9A8B-7224F9A5B992_4001_2">48702990</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1324247_1335482x1328677" id="id_8322447_3AB455E3-39D4-44BE-B83D-AAC0C50E3DFA_1001_1">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1324247_1335482x1331874" id="id_8322447_3AB455E3-39D4-44BE-B83D-AAC0C50E3DFA_2001_0">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1325519_1335482x1328677" id="id_8322447_3AB455E3-39D4-44BE-B83D-AAC0C50E3DFA_3001_5">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1325519_1335482x1331874" id="id_8322447_3AB455E3-39D4-44BE-B83D-AAC0C50E3DFA_4001_4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1330541_1335482x1328677" id="id_8322447_3AB455E3-39D4-44BE-B83D-AAC0C50E3DFA_5001_3">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1330541_1335482x1331874" id="id_8322447_3AB455E3-39D4-44BE-B83D-AAC0C50E3DFA_6001_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1348884" id="id_8322447_3AB455E3-39D4-44BE-B83D-AAC0C50E3DFA_7001_8">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1349273_1335482x1328677" id="id_8322447_3AB455E3-39D4-44BE-B83D-AAC0C50E3DFA_8001_7">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1349273_1335482x1331874" id="id_8322447_3AB455E3-39D4-44BE-B83D-AAC0C50E3DFA_9001_6">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <mnkd:SaleOfCommonStockInUnderwrittenPublicOffering contextRef="eol_PE126000--1610-Q0008_STD_29_20160531_0" unitRef="shares" decimals="0" id="id_8322447_DD4BE7D3-96AD-48AC-9FBC-9C35FC88D9FD_1_0">48543692</mnkd:SaleOfCommonStockInUnderwrittenPublicOffering>
  <mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="eol_PE126000--1610-Q0008_STD_29_20160531_0" unitRef="iso4217_USD" decimals="-5" id="id_8322447_DD4BE7D3-96AD-48AC-9FBC-9C35FC88D9FD_1_2">47400000</mnkd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
  <mnkd:SaleOfCommonStockInUnderwrittenPublicOffering contextRef="eol_PE126000--1610-Q0008_STD_29_20160531_0_1327036x1532316" unitRef="shares" decimals="0" id="id_8322447_4BEA620A-A767-4AC8-9844-4A68E275984E_1001_0">48543687</mnkd:SaleOfCommonStockInUnderwrittenPublicOffering>
  <mnkd:ClassOfWarrantOrRightExpirationPeriod contextRef="eol_PE126000--1610-Q0008_STD_29_20160531_0_1333769x1344495" id="id_8322447_4BEA620A-A767-4AC8-9844-4A68E275984E_2001_7">P30M</mnkd:ClassOfWarrantOrRightExpirationPeriod>
  <mnkd:ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable contextRef="eol_PE126000--1610-Q0008_STD_29_20160531_0_1333769x1344495" id="id_8322447_4BEA620A-A767-4AC8-9844-4A68E275984E_2001_6">2017-05</mnkd:ClassOfWarrantOrRightsMonthYearFromWhichWarrantsOrRightsExercisable>
  <mnkd:ClassOfWarrantOrRightExpirationPeriod contextRef="eol_PE126000--1610-Q0008_STD_29_20160531_0_1333769x1514964" id="id_8322447_4BEA620A-A767-4AC8-9844-4A68E275984E_3001_5">P2Y</mnkd:ClassOfWarrantOrRightExpirationPeriod>
  <mnkd:IssueOfWarrantsToPurchaseSharesOfCommonStock contextRef="eol_PE126000--1610-Q0008_STD_29_20160531_0_1335482x1328677" unitRef="shares" decimals="0" id="id_8322447_DD4BE7D3-96AD-48AC-9FBC-9C35FC88D9FD_1001_1">48543692</mnkd:IssueOfWarrantsToPurchaseSharesOfCommonStock>
  <mnkd:LoanAgreementWithRelatedParty contextRef="eol_PE126000--1610-Q0008_STD_31_20071031_0_1326002x1335383" unitRef="iso4217_USD" decimals="-5" id="id_8322447_86981D09-EC2E-4A11-8D33-54F423FFF3B4_2001_0">350000000</mnkd:LoanAgreementWithRelatedParty>
  <mnkd:LoanAgreementWithRelatedParty contextRef="eol_PE126000--1610-Q0008_STD_31_20131031_0_1326002x1335383" unitRef="iso4217_USD" decimals="-5" id="id_8322447_86981D09-EC2E-4A11-8D33-54F423FFF3B4_2002_0">370000000</mnkd:LoanAgreementWithRelatedParty>
  <us-gaap:ImpairmentChargeOnReclassifiedAssets contextRef="eol_PE126000--1610-Q0008_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_8322447_4E197731-92B2-4C23-9057-C97AFB5B191B_1_0">140400000</us-gaap:ImpairmentChargeOnReclassifiedAssets>
  <mnkd:LossesOnPurchaseCommitments contextRef="eol_PE126000--1610-Q0008_STD_365_20151231_0" unitRef="iso4217_USD" decimals="0" id="id_8322447_53734037-3993-4303-B9C6-8664395CE91D_6_10">66000</mnkd:LossesOnPurchaseCommitments>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE126000--1610-Q0008_STD_42_20160512_0_1333769x1514964" unitRef="iso4217_USD" decimals="-3" id="id_8322447_5B554D8B-F74C-4303-BA0F-0B253C4313AB_1001_1">5306000</us-gaap:FairValueAdjustmentOfWarrants>
  <mnkd:ClassOfWarrantIssuanceDate contextRef="eol_PE126000--1610-Q0008_STD_42_20160512_0_1333769x1514964" id="id_8322447_5B554D8B-F74C-4303-BA0F-0B253C4313AB_1001_2">2016-05-12</mnkd:ClassOfWarrantIssuanceDate>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="shares" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_13">401018000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_12">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:SalesRevenueNet contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_0">0</us-gaap:SalesRevenueNet>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0DBC9591-D373-40CA-9E57-52462361A9EB_2_2">1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_6">-24051000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_11">-28910000</us-gaap:NetIncomeLoss>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0DBC9591-D373-40CA-9E57-52462361A9EB_2_4">-28909000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_10">3000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_7">-10000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0DBC9591-D373-40CA-9E57-52462361A9EB_2_3">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0D920E6C-6368-43EE-9362-B44DAB6E09F6_2_0">1775000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6341079E-0A0E-40E2-BC86-72199EC7DC79_2_0">2740000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_8">721000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_2">7737000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_3">10623000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_5">24051000</us-gaap:CostsAndExpenses>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_9">4131000</us-gaap:InterestExpenseDebt>
  <us-gaap:ManufacturingCosts contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_2_4">5691000</us-gaap:ManufacturingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0_1324529x1373094" unitRef="iso4217_USD" decimals="INF" id="id_8322447_E88BDEA2-16AC-439A-9986-152F9395BFAD_1003_0">0</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0_1325994x1441734_1326002x1454078" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E006D4E8-8B23-4465-A73B-3D7CDAF2205D_1002_0">65000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_8322447_1CA604D8-267A-4D12-BC8D-7F080DD021ED_1002_1">380000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE126000--1610-Q0008_STD_91_20150630_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_8322447_1CA604D8-267A-4D12-BC8D-7F080DD021ED_1002_0">9000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-Q0008_STD_91_20160331_0" unitRef="shares" decimals="INF" id="id_8322447_EE6EC0CE-60AA-4AB3-A13A-E350A86D49E5_1_1">2364200</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE126000--1610-Q0008_STD_91_20160331_0" unitRef="shares" decimals="INF" id="id_8322447_EE6EC0CE-60AA-4AB3-A13A-E350A86D49E5_1_2">4920267</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-Q0008_STD_91_20160331_0_1324199x1331109" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8322447_EE6EC0CE-60AA-4AB3-A13A-E350A86D49E5_1001_6">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE126000--1610-Q0008_STD_91_20160331_0_1324199x1331109" id="id_8322447_EE6EC0CE-60AA-4AB3-A13A-E350A86D49E5_1001_0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE126000--1610-Q0008_STD_91_20160331_0_1324199x1331109" unitRef="iso4217_USD" decimals="-5" id="id_8322447_EE6EC0CE-60AA-4AB3-A13A-E350A86D49E5_1001_4">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-Q0008_STD_91_20160331_0_1324199x1335583" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8322447_EE6EC0CE-60AA-4AB3-A13A-E350A86D49E5_2001_5">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-Q0008_STD_91_20160331_0_1324199x1335583" unitRef="iso4217_USD" decimals="-5" id="id_8322447_EE6EC0CE-60AA-4AB3-A13A-E350A86D49E5_2001_3">2200000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8322447_4980ED30-6448-42A4-9957-986EEC09FD32_1_3">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="shares" decimals="INF" id="id_8322447_8F658594-A9ED-483E-9018-9162B96B5361_1_1">1088050</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="shares" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_13">455305000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="shares" decimals="INF" id="id_8322447_8F658594-A9ED-483E-9018-9162B96B5361_1_2">1140200</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_12">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:SalesRevenueNet contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_0">0</us-gaap:SalesRevenueNet>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0DBC9591-D373-40CA-9E57-52462361A9EB_1_2">-2000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_6">-19124000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_11">-29959000</us-gaap:NetIncomeLoss>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0DBC9591-D373-40CA-9E57-52462361A9EB_1_4">-29961000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_10">26000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_7">-5959000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0DBC9591-D373-40CA-9E57-52462361A9EB_1_3">-2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_0D920E6C-6368-43EE-9362-B44DAB6E09F6_1_0">1355000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6341079E-0A0E-40E2-BC86-72199EC7DC79_1_0">589000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ForeignCurrencyTransactionLossBeforeTax contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-5" id="id_8322447_53734037-3993-4303-B9C6-8664395CE91D_5_8">2400000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_8">721000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_2">4310000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_3">11110000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_5">19124000</us-gaap:CostsAndExpenses>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_9">4181000</us-gaap:InterestExpenseDebt>
  <us-gaap:ManufacturingCosts contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0" unitRef="iso4217_USD" decimals="-3" id="id_8322447_6EB70958-1E53-4606-B8F1-6861326547B7_1_4">3704000</us-gaap:ManufacturingCosts>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1324199x1331109" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8322447_8F658594-A9ED-483E-9018-9162B96B5361_1001_6">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1324199x1331109" id="id_8322447_8F658594-A9ED-483E-9018-9162B96B5361_1001_0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1324199x1331109" unitRef="iso4217_USD" decimals="-5" id="id_8322447_8F658594-A9ED-483E-9018-9162B96B5361_1001_4">700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1324199x1335583" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8322447_8F658594-A9ED-483E-9018-9162B96B5361_2001_5">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1324199x1335583" unitRef="iso4217_USD" decimals="-5" id="id_8322447_8F658594-A9ED-483E-9018-9162B96B5361_2001_3">1000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1324529x1373094" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E88BDEA2-16AC-439A-9986-152F9395BFAD_1001_0">64000000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1325994x1441734_1326002x1454078" unitRef="iso4217_USD" decimals="-3" id="id_8322447_E006D4E8-8B23-4465-A73B-3D7CDAF2205D_1001_0">67000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1325994x1469303_1327036x1425803" unitRef="iso4217_USD" decimals="-5" id="id_8322447_B29FCC3D-C2BC-4E5D-AFF2-9EF7C0655A75_1002_2">300000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
  <mnkd:ProfitSharingAgreementAmount contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1325994x1469303_1327036x1425803" unitRef="iso4217_USD" decimals="-5" id="id_8322447_1E6AA981-3CAE-4325-ADCE-5220E7CF1B21_1001_4">300000</mnkd:ProfitSharingAgreementAmount>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_8322447_1CA604D8-267A-4D12-BC8D-7F080DD021ED_1001_1">433000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1328480x1426352" unitRef="iso4217_USD" decimals="-3" id="id_8322447_1CA604D8-267A-4D12-BC8D-7F080DD021ED_1001_0">9000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1330097x1333806_1330194x1327949" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8322447_4980ED30-6448-42A4-9957-986EEC09FD32_1001_1">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1330097x1333806_1330194x1327949" unitRef="shares" decimals="INF" id="id_8322447_4980ED30-6448-42A4-9957-986EEC09FD32_1001_0">4015000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="eol_PE126000--1610-Q0008_STD_91_20160630_0_1330097x1333806_1330194x1327949" unitRef="iso4217_USD" decimals="-5" id="id_8322447_4980ED30-6448-42A4-9957-986EEC09FD32_1001_2">3000000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
  <context id="eol_PE126000--1610-Q0008_STD_91_20160630_0_1330097x1333806_1330194x1327949">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20160630_0_1328480x1426352">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20160630_0_1325994x1469303_1327036x1425803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20160630_0_1325994x1441734_1326002x1454078">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SubleaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnkd:AlfredMannFoundationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20160630_0_1324529x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20160630_0_1324199x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20160630_0_1324199x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20160331_0_1324199x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20160331_0_1324199x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20160331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20150630_0_1328480x1426352">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20150630_0_1325994x1441734_1326002x1454078">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SubleaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnkd:AlfredMannFoundationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20150630_0_1324529x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_91_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_42_20160512_0_1333769x1514964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassAWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-05-12</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_365_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_31_20131031_0_1326002x1335383">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_31_20071031_0_1326002x1335383">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-10-01</startDate>
      <endDate>2007-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_29_20160531_0_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-03</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_29_20160531_0_1333769x1514964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassAWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-03</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_29_20160531_0_1333769x1344495">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassBWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-03</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_29_20160531_0_1327036x1532316">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:RegisteredOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-03</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_29_20160531_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2016-05-03</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1349273_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1349273_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1348884">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1330541_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1330541_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1325519_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1325519_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1324247_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1335427x1324247_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1333589x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1333589x1332392">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1333589x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1333589x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1328480x1426352">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1327036x1425803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1500563_1326002x1335383_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LoanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1500563_1326002x1335383_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LoanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1500563_1326002x1335383">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LoanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1469303_1327036x1425803_1327271x1443229">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">mnkd:OperatingLossSharingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1469303_1327036x1425803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1444803_1326002x1365453_1333456x1331776">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LetterOfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnkd:RelatedPartyDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1444803_1326002x1365453">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LetterOfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnkd:RelatedPartyDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1441734_1326002x1454078">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SubleaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnkd:AlfredMannFoundationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1325994x1367294_1326002x1335383">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:AmendedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324896x1324925_1327094x1328686_1328615x1373094_1334317x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324896x1324925_1327094x1325206_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324896x1324925_1325994x1469303_1327094x1325206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324529x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324497x1494756_1324896x1324925_1327094x1325206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0_1324497x1387193_1324896x1324925_1327094x1325206_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_182_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_181_20150630_0_1333589x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_181_20150630_0_1333589x1332392">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_181_20150630_0_1333589x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_181_20150630_0_1333589x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_181_20150630_0_1328480x1426352">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_181_20150630_0_1325994x1441734_1326002x1454078">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SubleaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnkd:AlfredMannFoundationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_181_20150630_0_1324529x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_181_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_1_20160414_0_1330148x1382533">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mnkd:InsulinMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-14</startDate>
      <endDate>2016-04-14</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_1_20160405_0_1327036x1425803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-05</startDate>
      <endDate>2016-04-05</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_1_20160405_0_1325994x1469303_1327036x1425803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-05</startDate>
      <endDate>2016-04-05</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_1_20150810_0_1328615x1373094_1330806x1324556">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-08-10</startDate>
      <endDate>2015-08-10</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_1_20150810_0_1328615x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-08-10</startDate>
      <endDate>2015-08-10</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_1_20140731_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <startDate>2014-07-31</startDate>
      <endDate>2014-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1349273">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1348884">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1334838">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1330541">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1325519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1324436">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1335427x1324247">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1328615x1483091">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:FacilityFinancingObligationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1328615x1380739_1334317x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1325994x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1324896x1324925_1328615x1483091">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:FacilityFinancingObligationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1324896x1324925_1328615x1380739_1334317x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1324896x1324925_1325994x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1324896x1324925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1324497x1494756_1324896x1324925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0_1324497x1494756">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1349273">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1348884">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnkd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1334838">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1330541">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1325519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1324436">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1335427x1324247">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1333769x1514964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassAWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1333769x1344495">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassBWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1330148x1382533">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mnkd:InsulinMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1328615x1483091">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:FacilityFinancingObligationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1328615x1380739_1334317x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1500563_1326002x1335383">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:LoanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1469303_1327036x1425803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325994x1359335">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1325880x1332226_1325994x1469303_1327036x1425803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324896x1324925_1328615x1483091">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:FacilityFinancingObligationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324896x1324925_1328615x1380739_1334317x1324465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324896x1324925_1325994x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324896x1324925_1325994x1359335">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324896x1324925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324529x1510602_1325994x1469303">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnkd:MortgageLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SanofiAventisMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324497x1494756_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324497x1494756_1324896x1324925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324497x1494756">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324497x1387193_1328480x1426352_1328615x1466792_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324497x1387193_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324199x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0_1324199x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20150930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20140923_0_1327036x1425803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnkd:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-09-23</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160531_0_1333769x1514964_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160531_0_1333769x1514964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassAWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160531_0_1333769x1344495_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160531_0_1333769x1344495">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassBWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160531_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2016-05-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20150728_0_1328615x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-07-28</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20150531_0_1325994x1441734_1326002x1454078">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnkd:SubleaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnkd:AlfredMannFoundationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-05-31</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20130701_0_1324497x1494756_1328480x1426352_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-07-01</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20130701_0_1324497x1494756_1328480x1426352_1328615x1466792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnkd:DeerfieldManagementCompanyLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnkd:MilestoneRightsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:TwoThousandNineteenNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-07-01</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160801_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2016-08-01</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160512_0_1333769x1514964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassAWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-12</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20160512_0_1333769x1344495">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnkd:ClassBWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-12</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20151130_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
    </entity>
    <period>
      <instant>2015-11-30</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20150810_0_1328615x1373094_1330806x1324556_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-08-10</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20150810_0_1328615x1373094_1330806x1324556">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-08-10</instant>
    </period>
  </context>
  <context id="eol_PE126000--1610-Q0008_STD_0_20150810_0_1328615x1373094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mnkd:SeniorConvertibleNotesDueTwoThousandEighteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-08-10</instant>
    </period>
  </context>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="sqft">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="iso4217_EUR">
    <measure>iso4217:EUR</measure>
  </unit>
  <unit id="D">
    <measure>utr:D</measure>
  </unit>
</xbrl>
